CA2128892C - Methods for the diagnosis and ablation treatment of ventricular tachycardia - Google Patents
Methods for the diagnosis and ablation treatment of ventricular tachycardia Download PDFInfo
- Publication number
- CA2128892C CA2128892C CA002128892A CA2128892A CA2128892C CA 2128892 C CA2128892 C CA 2128892C CA 002128892 A CA002128892 A CA 002128892A CA 2128892 A CA2128892 A CA 2128892A CA 2128892 C CA2128892 C CA 2128892C
- Authority
- CA
- Canada
- Prior art keywords
- thin layer
- myocardial
- ventricular tachycardia
- spared
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/363—Detecting tachycardia or bradycardia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/08—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by means of electrically-heated probes
- A61B18/082—Probes or electrodes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
- A61B18/24—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor with a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00292—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
Abstract
A closed-heart method for treating ventricular tachycardia in a myocardial infarct patient afflicted with ventricular tachy-cardia is disclosed.The method comprises, first, defining a thin layer of spared myocardial tissue positioned between the myo-cardial infarct scar tissue and the inner surface of the myocardium (the endocardium) of the patient, and then ablating the thin layer of spared myocardial tissue by a closed-heart procedure with an ablation catheter. Apparatus for carrying out the method is also disclosed. Also disclosed is a method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial in-farct patient not previously diagnosed as afflicted with ventricular tachycardia. The method comprises detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the en-docardium) in the patient.
Description
~1~~~~2 MR't'FiODS FOR 'THR DIAGNOSIS AND ASIATION
TR~ATMEIVT OF VEIVTRICUU~R TAChiYCARD1A
This invention was made with. Government support under grant numbers HL-28429, FiL-17670, and ~iL-33637 frOa~
the PTational Institutes of Health and grant number CDR-~62~~,~1 fr~yn the National Science Foundation. The Government'ha~ certain rights to this invention.
Field of the Invention This invention relates to methods for the ablation o~ :~s~d~ac tissue for the treatment of vsxatricstlar tachy~arciia and to diagnostic methods for detecting c~nditi~ns which indicate a high risk of ventricular tachycardia.
Rackoround of t#~~ Invent9ora Ventricular tachycardia is a disease of the heart; in whicta the heart's nox~nal rhythaQic contraction is altered, thus affecting heart function. The c~nciition is aften described as a heart beat which is too fast, alti~ough the di ease is far more complexs Ventricular tachycardia occurs most often in patients following a m~rocardial infarction. A myocardial infarction, commonly referred to as a heart attack, is a loss of bl~od flow to a region, of the heart causzng the ~ryocardial .muscle) tissue in that region to die and be replaced by an area ,~2~~~~
_2_ of scar tissue known as a myocardial infarct. In most cases, this occurs in the left ventricle.
Ventricular tachycardia ("VT") may be initiated' and sustained by a re-entrant mechanism, termed a "circus" movement. The mechanism of re-entry, as it is currently understood, is discussed in M. Josephson~and H.
Wellens, Tachycardias: Mechanisms, Diagnosis, Treatment, Chap. 14 (1984)(Lea & Febiger). Most cases of sudden cardiac death that have occurred during cardiac monitoring have begun as VT that degenerated into ventricular fibrillation.
63hile VT can be halted after it begins by pacing or cardioversion, it is preferable to prevent the arrhythmia from arising: Drug therapy has been used, but ~.5 , is successful in only 30 to 50 percent of patients and has undesirable side effects. Endocardial resection, a surgical procedure involving removing the tissue in the ventricle thought to be the source of the VT, has been reported to eradicate VT in up to 90 percent of patients, but a,t suffers from a 5 to 10 percent incidence of per~operata.ve mortalitys For a da.scussion of surg~,cal procedures, see T. Ferguson and J. Cox, Surgical Therapy far Cardiac Arrhythmias, in Nonpharmacological Therapy of Tachyarrhythmias (G: Breithardt et a1. eds. ~.~87).
As an alternative to surgery, the technique most often attempted is ablation. Typically, programmed premature pacing is performed from a catheter electrode ih the right or left ventricular cavity. During prcsgrammed premature pacing, a stimulus, usually of twice diastolic threshold, is repeatedly given prematurely, until either VT is induced or the tissue is too refractory to be excited. The ECG is examined during induced VT and compared to the ECG showing spontaneous bouts of VT. ~f the ECG is similar, it is assumed that 3.5 the patient's clinical VT is being induced. A mapping catheter in the left ventricular cavity is used to record from numerous sites sequentially to determine the _3~
activation sequence along the left ventricular endocardium during the induced VT. The site from which activation appears to originate during the induced VT is identified and assumed to be a portion of the reentrant pathway. The techniques of pace mapping and ~entrainment may then be used in an attempt to confirm or refine the localization of the region rising to VT. The region is then ablated. Unfortunately, this technique is usually unsuccessful unless repeated many times. For example, a.t has been reported by Downer et al. that for a similar -technique (the electrodes were located on an endocardial balloon instead of a catheter) , anywhere from 10 to 42 shocks through different electrodes were required to prevent the reinduction of VT. It is assumed that Z5 failures occur because ablation is not performed at the correct site or does not create a lesion deep enough taithin the ventricular wall to reach the reentrant pathway.
It is extremely desireable to prognose the likelihood of a myocardial infarct patient being susceptible to ventricular tachycardia. U.S. Patent No.
4;680,708 to M. Cain and B. Sobel suggests a method and apparatus for analyzing electrocardiogram signals to progno~e ventricular tachycardia, but the early detection . 25 of myocardial infarct patients susceptible to ventricular tachycardia remains a problem.
In view of the foregoing, an object of the present invention is to provide a technique which is effective in combatting VT, does not require the administration of drugs, and does nut require open°heart surgery.
A further obj ect of the present invention is to provide a means for prognosing the likelihood of ventricular tachycardia occuring in a myocardial infarct patient not previously c~.iagnosed as having ventricular tachycardia: _ . ., . . .. . .. _.:. . _ _ s. .::: ,., ,_, , , .. . _ .
,::..
,:
:.;.
a r e.; ,'. r > :r-i" ., . ":e x .
r i ;'~. . . . . _, . . _ , . , . ..
... .. . _ r. i::. . " . , e.. ~ ~~- . .. . . . ., . . , .. _ . . f , . . ..
", r .... ... . ':. r a :. .:..., ..,. . . .. .. . ... . . , .. , Summary of the Invention The present invention :is based on the concept that a thin layer of viable myocardial tissue adjacent to the endocardium in a myocardial infarct patient is capable of supporting multiple re-entrant pathways, any one of which can give rise to ventricular tachycardia.
In view of the foregoing finding, a first aspect of the present invention is a closed-heart method for treating ventricular tachycardia in a myocardial infarct patient afflicted with ventricular tachycardia.
The method comprises, first, defining a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the endocardium) of the patient, and then ablating the thin layer of spared myocardial tissue by a closed-heart procedure with an ablation catheter.
In a particular embodiment of the foregoing, the ablating step is carried out by creating at least one elongate lesion in said thin layer extending from the endocardium to the myocardial infarct scar tissue in a closed-heart procedure with an ablation catheter. The at least one elongate lesion is configured to reduce the size, in surface area, of any portion of the thin layer in electrical contact with the remainder of the endocardium sufficient to combat ventricular tachycardia in said patient. This may be carried out by electrically separating from the remainder of the endocardium a portion of the thin layer which has a size, in surface area, sufficient to combat ventricular tachycardia (e. g., by creating a continuous elongate lesion around the thin layer of spared myocardial tissue, the continuous lesion encircling the thin layer to electrically separate the thin layer from adjacent myocardial tissue), or by creating at least one (or a plurality) of elongate lesions in the thin layer, wherein the at least one elongate lesion divides the the layer into a plurality of electrically separated portions, with the capability of ' CA 02128892 2001-11-20 spared endocardial tissue connected to the intraventricular catheter, and an analyzing means operatively associated with the detecting means for prognosing the likelihood of ventricular tachycardia arising from the thin layer.
Another aspect of the present invention is an apparatus for ablation treatment of ventricular tachycardia. The apparatus comprises an intraventricular catheter, a detecting means for detecting a thin layer of spared endocardial tissue connected to the intraventricular l0 catheter, and an ablation means for ablating the thin layer of spared endocardial tissue connected to the intraventricular catheter.
Another aspect of the present invention is a method for prognosing the likelihood of ventricular tachycardia occurring in the myocardial infarct patient not previously diagnosed with afflicted with ventricular tachycardia. The method comprises detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the endocardium) in the patient.
In accordance with one embodiment of the present invention, there is provided the use of an apparatus comprises:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
analyzing means operatively associated with said detecting means for determining from the detected boundaries of the thin layer of spared myocardial tissue -5 a-the likelihood of ventricular tachycardia arising from said thin layer; and ablation means for ablating said thin layer of spared myocardial tissue connected to said intraventricular catheter, to treat ventricular tachycardia.
In accordance with another embodiment of the present invention, there is provided the use of an apparatus comprises:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
analyzing means operatively associated with said detecting means for prognosing the likelihood of ventricular tachycardia arising from said thin layer; and ablation means for electrically separating a portion of the thin layer of spared myocardial tissue sufficient in size to combat ventricular tachycardia from the remainder of the myocardium, to treat ventricular tachycardia.
In accordance with another embodiment of the present invention, there is provided a method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium in said 3o patient and determining whether said thin layer of spared myocardial tissue is capable of supporting re-entrant pathways.
~ ' CA 02128892 2001-11-20 -5b-In accordance with another embodiment of the present invention, there is provided a method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium in said patient and determining that the thin layer has a myocardial surface area of at least 15 square centimeters.
In accordance with another embodiment of the present invention, there is provided a method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
creating a map of the locations of the thin layer identified in said determining step to define the layer areas, and evaluating the dimensions of said thin layer areas to determine if the contiguous portions of thin layer areas are of sufficient size to support re-entrant pathways.
In accordance with another embodiment of the present invention, there is provided an apparatus for prognosing the likelihood of ventricular tachycardia in a myocardial infarct patient, the apparatus comprises:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned -Sc-between the myocardial infarct scar tissue and the inner surface of the myocardium; and analyzing means operatively associated with the detecting means for determining from the detected boundaries of the thin layer of spared myocardial tissue the likelihood of ventricular tachycardia arising from said thin layer.
In accordance with another embodiment of the present invention, there is provided an apparatus for prognosing l0 the likelihood of ventricular tachycardia in a myocardial infarct patient, the apparatus comprises:
an intraventricular catheter;
detecting means for detecting the locations of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium; and analyzing means operatively associated with said detecting means for creating a map of the locations of the thin layer detected by the detecting means to define the thin layer areas and evaluating the dimensions of the thin layer areas to determine if the contiguous portions of the thin layer areas are of sufficient size to support re-entrant pathways.
Previous work in the diagnosis and treatment of ventricular tachycardia has always looked for functional or electrical characteristics of tissue rather than a specific anatomic structure. The present invention, in contrast, is based on the finding that a specific macroscopic anatomical structure gives rise to ventricular tachycardia.
~ ' CA 02128892 2001-11-20 -Sd-Brief Description of the Drawings Figure 1 is a side view of a human heart, with portions cut away to reveal the internal chambers and mycardial walls.
Figure 2 illustrates typical cross-sectional slices from control (Fig. 2A), subacute ventricular -s-tachycardia (Fig. 2B), and chronic ventricular tachycardia (Fig. 2C) groups:
Figur~ 3 schematically illustrates various ablation patterns on the internal surface of the heart which may be employed in carrying out the -present invention.
F'ic~ura ~ schematically illustrates an apparatus useful for carrying out the ablation method of the present invention.
20 Figures 5-6 illustrate the use of an apparatus as given in Figure 4.
~'igur~ 7 shows the initiation of sustained ventricular tachycardia settling into a monomorphic figure of 8 reentry pattern. The activation times end isochrc~nal maps of the last beat of the S1 train (Panel A) are shown; as Well as the first 5 beats of VT (Panels ~-F)' 'induced after a 20 mA S2 stimulus at an S1S2 interval of 210 ms as recorded by a plaque of 121 bipolar eledt~°odes over the infarct in the left ventricle. The 511 interval: of the' pacing train is 300 ms. The long axis of the spared myocardial fibers is represented by the double headed arrow at the top of the figure. each number gives the activation time in ms at an electrode sate. The is~chr~nal interval is 20 ms. In panel ~ time 2~ zero ~a the beginr~zng of the S1 stimulus. In Panels B-F
time zero is the beginning of the 52 stimulus. 7Cn panel 8, the first beat after S2 sti~a~lation; arrows indicate that the activation fronts conduct, around both sides of a'line of bl~~k (reepresented by the hea~ay black bar in ~0 ':this and subsequent figures). The hatched line (ia~ this and subsequent figures) represents a frame line between 'panels in which reentry is believed to occur. In panel C; the adjoining solid and hatched lines indicate block between beats one and two and reentry between beats two 35 and three respectively. Panel 2 shows the monomorphic ventricular tachycardia as recorded by the surface leads I, II and ITI. Closed arrow indicates S2.
_~_ F'iguse 8 shows the initiation of sustained monomorphic ventricular tachycardia with a figure of 8 reentry pattern in a second animal in which the S1 was delivered from the tight ventricular free wall. The activation times and isochronal maps of the last beat of the 300 ms S1 train (Panel A) as well as those of the first '3 beats of ventricular tachycardia (Panels B-D) induced by a 30 mA S2 stimulus at an S1S2 interval of 230 ms are shown. In panel E, the activation pattern of the 1.0 first beat post S2 stimulation is compatible with figure of 8 reentry: ~ The initial activation sequence is directed back toward~the S1 stimulation site in the direction opposite the S1 activation sequence. Figure of 8 reentry is also seen in the subsequent beats of ventricular tachycardia (Panels C and D). Panel E shows the lead II rhythm strap of ventricular tachycardia induced. ~pen arrow indicates the first 31 and closed arrow indicates S2. The long axis of the spared myocardial fibers i~ represented by the double headed 20' arrow at the top of the figure.
gigue g shows the initiation of sustained ~noa~omorphic ventricular tachycardia with a figure of 8 reentry pattern in which the S1 was delivered from the left ventricular free wall in the same animal as for Fig.
8. The activation times and isochronal maps, of the last beat of the 30O ms Sl train (Panel A) as well as those of the first 3 beats of ventricular tachycardia (Panels B~D) induced by a 3Q mA S2 stimulus at an S1S2 interval of 230 ms, are shown. In panel B, the activation pattern of the first beat post S2 stimulation is compatible with figure 'of 8 reentry and once again the initial activation is generally back toward the S1 stimulatian site in the diredtion opposite the S1 activation sequence. Figure of 8 reentry is also seen in subsequent beats (Panels C and D). Panel E shows the Lead II rhythm strip of ventricular tachycardia induced. span arrow indicates the first S1 and closed arrow indicates S2.
t r i w ,.. -...-t . i~ .'.
F a S
., n,v..,., ::,4 ~.a t , .. . ,. .. . , a ~~ -' . . . .. . .. < , a .. .. .,. r. . .-i-...n.,.
.n..,.. ... .... .". ... ... .. . .. < . .. ._... . . ..... s.... ._.... .
.v., . . W . , n . .id,i.i.. a , ..ut . ., W W..... r.. .. 5..... ,. .. ..,..
~8_ Detailed Descri tp ion of the invention The basic anatomy 'of the human heart 1~ is illustrated in Figure 1. Its walls are composed primarily of myocardial (muscle) tissue. The muscle tissue walls of the heart are referred to as the myocardium 11. The inner surface of the myocardium, which is in contact with the blood in the heart chambers, is the endocardium 12,12,. The heart is longitudinally divided into left and right halves. Each half has an upper chamber called an atrium 13,14, and a lower chamber called a ventricle ~1~,16. Between the atrium and the ventricle of each half is an atrioventricular (AVM valve 1? which is a one way valve allowing blood flow only from the aarium into the ventricle. The right and left ventricles are separated by the interventricular septum ~~ .
the circulatory system is comprised of two separate systems, pulmonary and systematic circulation.
~n the paal,monary circuit blood is pumped by the right ventricle 15 into the pulmonary artery which then splits info a right pulmonary artery 2~ and a left pulmonary artexy 21 allo~ring t:o flow through the lungs and then info the pulmonary veins 22,23,24,5 which fi~w into the lift atrium 14: The oxygen rich blood from the pulmonary 2~ circuit is pumped by the left ventricle into the systemic circui% via the a~rta. defter passing throughout the body, the blood returns to the right atrium via the inferior vents cave and the superior vane cave, The thic)cness of the walls of the chambers of the hearts vary in relation to the amount of pua~pinc~ worDc they perform. The atria 13, 14 are of little importance in pumping the blood except under high demand conditions, such as exercise, and are thin walled ~2-3 millimeters).
The right ventricle 1~ only pumps blood through the 3~ relativeay short pulmonary circuit and' is significantly more thin walled than the left ventricle 16. which must r .s.r.~..=s. .. . ..... ~ ..:: .,.. .... . . . . . . .:~ : .. .
~~.2~~~~
maintain the pressure within the systemic circuit (8-12 millimeters). -F$c,~ure 2 illustrates typical cross-sectional slices of ventricles from patients with myocardial infarction but no ventricular tachycardia (control, (Fig.
2A), patients with subacute myocardial infarction with ventricular tachycardia (Fig. 2B), and patients with chronic myocardial infarction with ventricular tachycardia (Fig. 2C) groups. The subacute group had predominantly large solid myocardial infarcts 30 with -ribbon spared subendocardium 31. The chronic ventricular tachycardia group has predominantly -large patchy myocardial infarcts 32 with irregular spared subendocardium. The control group had smaller hearts and smaller more randomly distributed patchy myocardial infarcts 34 with little ribbon spared subendocardium 35.
sla~.k represents solid myocardial infarct, and stippling represents patchy myocardial infarct. Slices are seen fr~m the basal aspect. These data are. known. See D.
~Olick et al., Circulation 74, 1266, 1273 (1986).
The thia~ layer referred to herein is a layer of surviving myocardial tissue located between the surface of the endocardiuan 12,12' and the myocardial infarct scar tissue. The thin layer may be in the right or left ventricle, lbut moxe typically the left ventricle. A
layer of fib~°osa.s may be positioned beneath the thin layer, as explained below. WD°iile the precise dimensions ;~f the thin layer will vary from patient to patient; with some va~~.ability due to the variability of the infarct in the epi.cardial to endocardial dimension, tlae thin layer 'Will generally have a thickness of up to about 5 millimeters, and will generally have an endocardial surface area of at least 15 square centimeters.
Typically, the thin layer will have a thickness of from about .25 to 2 millimeters, and will have an endocardial surface area of from about 20 to 40 square centimeters.
~1~~~~~
The present invention is directed to both diagnostic and treatment - methods for ventricular tachycardia in a patient afflicted with a myocardial infarct. The treatment method of the present invention involves first, defining a thin layer ~ of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the endocardium) of the patient, and then ablating the thin layer of spared myocardial tissue. The diagnostic method provides a means for eatamining myocardial infarct patients to determine their risk of developing ventricular tachycardia by detecting the presence of a thin layer of spared myocardial. tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the endocardium).
Reentrant pathways causing ~7T may arise from numerous sites within the thin layer of spared tissue between the infarct and the endocardium, the first or defining step involves identifying the presence and 2A location of this thin layer instead of inducing and mapping the activation seeiuence during a particular ~:mcidence of induced 'VT as was done previously. Thus, the subject on which the defining step is performed need ~o.~ have VT induced prior to the procedure, and need not be a;n VT during the deffining step.
The thin layer can be defined by any one or a combination of several techniques, including (1) analyzing rec~rdings during regular rhythm from electrodes on a catheter: (2) pacing from an electrode on 30 the catheter and analyzing the pac~.ng threshold as well 'as recordings of the pacing stimulus and the ensuing activation sequence from other electrc~dcs on the same catheter: (3) direct visualization of the thin layer of spared myocardial tissue by an raging technique such as 3~ echocardiography/ultrasound which can differentiate healthy myocardial tissue from infarc~ed tissue; (4) detecting by echocardiography the infarct itself .;s-..~ t. ~.- ..
,r : ..~,.,_ ~,.
.~
,.
, . . .--: :. - :- , ; . . . . .. ~ . -. ; . a . ..: : .... .
.. . . ..,.. . ... . .. . . . . ..y.. .. ..... .. . ,.. ... ......:: ., . ,..
. ;. . .. .
E
overlying the thin layer of spared myocardial tissue (e. g., by detecting altered heart wall motion overlying the infarct or by detecting altered backscatter from the infarct); (5) visualization of endocardial fibrosis beneath the thin layer of spared myocardial tissue (i.e., between the thin layer of spared myocardial tissue and the ventricular cavity); and (6) electrically stimulating the endocardium to detect an increased -pacing threshold (due to the presence of endocardial fibrosis overlying the thin layer of spared myocardial tissue).
Any suitable apparatus may be employed to carry out the defining step, such as a catheter .mounted echocardiographic ultrasound crystal sensor inserted into the interior of the. heart of said patient, an echocardiographic ultrasound crystal sensor positioned in 'the esophagus of the patient, or echocardiographyic u~,txa~ound crystal sensor applied to the chest wall by contact to the skin. The imaging device need not be on catheter. (is in the case of an esophageal 2d echoc~rdiograph); though preferably the mapping is performed with a catheter mounted sensing device.
Particularly suitable is an echocardiagraphic,ultrasound crystal. sensor mounted on a catheter whiclh is inserted iz~tb the interior ~f the heart of the patient. This sane ca~tJheter can also carry the ablation device as discussed be3.ow: Suitably detection devices are known, examples of Which are disc~:OSed in U.S. Pat. N0. 5,Oa0,185 and in PCT
Application Nt~mb~r i~0 91/0288. (Applicants intend that all U:S. Patent references cited herein be incorporated herein by reference). An ultrasonic technnque,, for.
capping myocardial tissue with an external sensor is discussed In ~ s ~ar~llal et al s , ~o rlJl6e ~~~r . SICTI6d a ~, 17~-186 (~.~88)(showing altered backscatter from myocardial infarct).
Once the thin layer of spared myocardium is identified, it can be ablated by a variety of methods.
Three such methods of the present invention, along with prior art methods, are schematically illustrated in Figur~ 3. The endocardial- surface is schematically illustrated in Fig. 3A, the prior art surgical resection technique is illustrated ~in Fig. 38, and prior art catheter ablation techniques are sc~aematically .
of the illustrated in Fig. 3C. In the embodiment invention illustrated in Fig. ~D, ablation is accomplished by creating a continuous lesion ~l extending from the endocardiu~ to the myocardial infarct scar tissue around the thin layer of spared myocardial tissue.
This Continuous lesion encircling the thin layer electrically isolates the thin layer from adjacent myocardial tissue so that any arrhythmias arising in the thin layer are not able to propagate into the rest of the heart. In the embodiment of the invention illustrated. in Fig. 3E, ablation is accomplished by creating at least one, ~r as illustrated a plurality of, elongate lesions ~~ ~.r~ the thin layer, with each lesion extending from the endocardium to the myocardial infarct scar tissue. The elongate lesi~n (s) are patterned to divide the thin layer fnto a plurality of electrically separated portions each, of which is substantially incapable of originating ventricular tachycardia. In the embodiment of, the inven~.ion illustrated in Fig: 3F, ablation is accomplished by destroying all of the thin layer of sp~.red myocardial issue with a large lesion ~3.
~A Vara.ety of devices ars known and available for performincj the ablation step: A. direct current ablation electrode such as that disclosed in tl.S. Pat.
No: x,896,671 csr a laser ablation catheter such as that disclosed' 1r~ U:S. Pat. No. 4,985,028 may be u~~d. More preferably, a radib frequency (RF) ablati~n catheter as disclosed in U:S: Pat. No. 4,945,91 or a microwave ablation catheter such as that discussed in J. Langberg et al.., Pace 1~, 2105 (December, 1991) is used. Another approach is to ablate the thin layer with ultrasound at high energy, as discussed in greater detail below.
_....... _.._ z. . .. . . .. . .. .. , .. .,.~,~. , .. . , . . .., ra . ~'f.' ... ...... . ,..,... , ~~2gb9~
As noted above, both the detecting means such as an echocardiagraphic/ultrasound crystal sensor and an ablation means such as a laser unit may advantageously be located-on the same catheter. Examples of such catheter devices are disclosed in U.S. Pat. No. 5,000,185, U.S.
Pat. No. 4,936,281 and in PCT Application Number WO
91/02488. A schematic diagram of such a catheter device using and ultrasound sensing means and a laser ablation means is shown in Figur~ 4. The system 5a includes a l0 catheter probe assembly 51 including a distal subassembly 52 inserted within a guide catheter 53. The proximal end of the guide catheter 53 is coupled to a conventional side arm connector 54. The distal subassembly 52 is coupled to a suitable motor means 55 which provides the d~~.ve to maneuver the distal subassembly 52. The ultrasonic imaging components within the distal subassembly 52 are electrically connected with an electroacoustic transducer and an ultrasound transceiver 5~ via suitable electrical contact brushes 57. To perform detection the ultrasonic imaging coMponents wa:thin the distal subassembly are activated and the received signals are processed by the ultrasound transceiver 5fs. The signals are further processed by algorithms gerfor~ed by the computer 5~ to generate an a.mage of the tissue structures reflecting the ultrasonic energy toward the distal subassembly 52. The ablating is ~aerf~rmed by a laser means. A laser driver 60 provides a source of ~.aser radiation which passes via the contact brushes 57 to a dual function eiectrical/optical ~0 c~nnector 6i which couples tlae ultrasonic ianaging components and laser optical components within the distal subassembly 52 to the ultrasound transceiver 55 and the laser driver ~0. The computer 5~ also functions to allow the operator to control the laser driver to perform ablation of tissue where desired.
A software program running in the computer 5~, which computer is operatively associated with the ~1~~~~~, detecting means, provides a means for prognosing the likelihood of ventricular tachycardia arising from said thin layer. In a typical embodiment of this method, the detecting step includes determining if a thin layer of spared tissue exists between the infarct scar tissue and the endocardium, then creating an anatomical map of the locations of the thin layer identified to define the thin layer areas, .and then evaluating the dimensions of the thin layer areas to determine if the contiguous portions e~f these areas are of sufficient size to support reentrant pathways.
Another option in an apparatus of the present invention is, as noted above, to use ultrasound energy at higher power lwels to ablate the thin layer of tissue.
An intraven~cricular catheter for accomplishing ,this method w~uld have two sets of ultrasound crystal connected thereto: one set configured for detecting the ~p~in layer, arid another set configured for ablation of the thin layer:
Figures 5-6 illustrate the use of a catheter of Fa.gw 4 ire a method of the present invention. The catheter 5l is first introduced into the circulatory .system, preferably through a vessel in the leg, and advanced into the heart l0. In the typical case of a ~5 patient suffering from VT follawing a myocardial i~farctzan, the infarct scar tissue is located in the lift ven~r~.cle l6,' either within the outer walls of the ventricle or within the interventricular septum 3.~. In such a patient, the catheter is advanced into the left 30 ventricle 16, for example by advancing the catheter into ' the femoral artery and then through the aorta ~6 into the left ventricle l~. The detecting means is then activated and the catheter is manipulated substantially throughout the left ventricle l6 to locate any areas of thin layers 35 of sua-viving tissue between the endocardium ~2 and the infarct scar tissue. Preferably, this information is r~'.~~'i~- :r~J z. ~i:,.,J'.. $4f ~~..~~,~"5 . ..........,... ,.~. ........ .. .., .s". .. " ...,.., ...;..l..
L.~..sdsPl9~'.'an. .., .. :','::Z'r:'1'~: ., ,/.r..".....~.lo-..t,.. N.
",...rvn.. v...n.ei....:. f......l.,.f~M',p.~°~l~.o..,... ,.... .... .
. a.. ,..
~~2~~~'~
~~~~
generated for substantially the entire area affected and then the catheter is withdrawn.
In the treatment of the present invention, each thin layer area located is rendered substantially incapable of supporting VT by the ablating step. The ablating step may be performed for alI the thin layer areas found after the mapping is completed or, more preferably, is performed on each contiguous thin layer area once the area is defined. The portions of tissue to be ablated depends upon the embodiment of the present invention utilized~as was discussed previously.
The ablating step is optionally followed by the step of verifying that the thin layer of spared myocardial. tissue is no longer capable of originating a ventricular tachycardia. This verifying step can be accomplished msing a programmed pacing technique to induce ventricular tachycardia. Such techniques are discussed in M: Josephson and H. wellens, Tachycardias:
Mechanisms, Diagnosis, Treatment, Chap. l4, X1984).
As noted above, the present invention further provides a method for prognosing the likelihood of ventricular tachycardia occuring in a myocardial infarct patient not previously diagnosed as afflicted with uentricul~r ta~hycardia. The method comprises detecting a thin layer ;of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner ~uxface of the myocardium the endocardium) in the P~'~icn'~. The thin layer to be detected is described in detail above: The procedure is advantageously carried.
out by closed-heart procedures, as discussed in, detail above. ~ ~n a typical embodiment of this method, the detecting step includes determining if a thin layer of spared tissue exists between the infarct scar tissue and the endocardium, then creating an ana~ramical map of the locations of the thin layer identified to define the than layer areas, and then evaluating the dimensions of the thin layer areas to determine if the contiguous portions ;o r ,~
-ls_ .
of these areas are of sufficient site to support reentrant pathways.
The present invention is explained further in the following Example. This Example is illustrative of the present invention, and is not to be construed as limiting thereof.
high current Stimuli to the Spared Ep cardium of a ~arg~ ~Cmfmret gnduc~ ~entricular Ta~chycardia This study was carried out to test the hypothesis that a high current premature stimu3.us during the vulnerable period over the surviving epicardium of a f~ur day old infarct in a canine model will induce sustained V'.C' rather than ventricular fibrillation. As explained in detail below, it Was found that a large S2 over ~a nontransmural infarct induced VT if the spared myocardium was thin> .
1~'fERI~Ir~ ~1'D ~IE'g!H~DS
Surgical ureparation. In twelve mongrel dogs, anesthesia was induced using intravenous thiopental sodium, 20 mgfkg, and maintained using a continuous ~.nfusi.~n of thiopental sodium at a maintenance rate of ,appr~ximately 0, 8 angfkg/min. Succinylch~line, 1 mgJ~cg, was also given at the time of anesthesia induction. The animals were incubated with a cuffed: endotracheal tube and ventilated with room air and oxygen thr~u~h a Harvard respirator (Harvard Apparatus ~o. South Id~~i.~k; MA): A
~~m~ral arterial Tine and two ~:ntr~ven~us lines were insex~edl using sterile technic~aaes. Syst~i~ic agterial 0 pressure was continuously displayed. Arterial blood samples were drawn every 30°60 min for determa.nation of pH, PA2, Pe02, base excess, bicarbonate, ~a~', K'', and ~a~'' content. Ringer°s lactate was~continuously infused via a peripheral intravenous line. This was supplemented 35 with sodium bicarbonate, potassium~chloride, and calcium ,=..l ~ , .
,.:
'.. f P.~ ::..
o-.~y. ..
.. f'.:
.. h t 0. !.
~ n . n, .
W.,v:
r , 1;,.u r I. 4 , H
o . . , ..u, ~ . . . , n . . , . . . _ 1 . . ... ~ , . . . ,. , .. .. , ....,......,...,... . .. . , ,. . .J,~fi-:° . ." .._.. r. . ..
i:.:m , .., ......,., ,.... .. ,.. .",.. .... n. .. . ..
21~~~~~
_1,_ chloride as indicated to maintain pH and electrolytes within normal values. Electrocardiographic leads were applied for continuous ECG monitoring. Eody temperature was maintained with a thermal mattress. With sterile surgical techniques the heart was exposed through a left thoracotomy at the fourth intercostal space; the pericardium was opened, and the left anterior descending coronary (hAD) artery was dissected free at the tip of the left atrial appendage. A noose occluder was placed around the left anterior descending artery and it was occluded by the Harris two state procedure (A. Harris and A. Rojas, Exp. Med. Sung. l, 105 (1943)). In order to ensure sparing of the epicardium in the entire infarct zone, partial occlusion was maintained for 30 min, followed by complete occlusion for 90 min prior to reperfusion. Five minutes before initiation of partial occlusion and again before the terma.nation of complete occlusion the- animals were pre-treated with bolus alnjections of intravenous lidocaine (2 mg/kg). A second bales of lidocaine (1 mg/kg) was administered ten minutes latex. The chest was closed in layers, evacuated under negative pressure and the animal was allowed to recover.
Four'days after LAD occlusion, anesthesia was , induced with intravenous pentobarbital (30-35 mg/kg body ~5 w~:fight) and maintained with a continuous infusion of pent~barbital at a rate of approximately 0.05 mg/kg per min guccinylcholine (1 mg/kg) Haas also given intravenously, at the time of anesthesia induction.
S~Qplemental doses of 0.25 of 0.5 mg/kg of 3A ~uccinylcholin~ were given hourly as needed to r~a~.r~tain meascle re~.ax~tion. The animals were ventilated, hemodynamically monitored and maintained as described above. A median sternotomy was performed, and the heart was suspended in a pericardial cradle. The recording 35 apparatus consisted of 121 bipolar Ag-AgCI epicardial electrodes (see F. Witkowski and P. Penkoske, Am. J.
Phys~ol. 254, H804 (1988)) arranged in 11. columns and 11 _1g_ rows mounted in a 4X4 cm plaque. Each epicardial electrode was 1 mm in diameter. There was a 2 mm intra-electrode distance between eaeh member of the bipolar pair and an inter-electrode distance of 4 mm. This plaque also contained a centrally located stimulating electrode. The plaque of epicardial recording electrodes was sutured ~ver the infarcted anterior surface of the left ventricle. Four solid stainless steel wires t:~terican Wire Gauge # 30, Cooper Wire Co. Chatsworth, CA) that were insulated except at the tip were positioned for S3 pacing from the lateral right ventricle, the right ventricular outflow tract, the lateral left ventricle seed the posterior left ~rentricle. Defibrillating patches mere sutured over the right atrium and upper portion of the lateral right ventricle and the posterior apical left ventricle to deliver cardioversion or defibrillation shocks. Limb leads I, II and III were recorded with limb lewd IT filtered from 50 Hz to 300 Hz so it recovered quickly after'large premature stimuli.
Data ~cc~u~.sition. A computer assisted-mapping system capable of simultaneously recording 128 channels was used to record the stimulus potentials in unipolar mode with the left leg as reference and the activation complexes in bipolar mode. See P. Wolf ~t al., ~r Method of Measuring Cardiac Defibrillation Potentials, Pros.
~CEM.S Ealtimore; Md., 4 t1986)(The Alliance for Engineering in Medicine and biology, Publishers).
Signals were redorded digitally at a rate of 1,000 samples per second with a low gees filter at 500 Hz and . the high-pass filter at 5 Hz. See W. Smith et al., ~Pxoceedings cg computers in cardiology, 1~1 ~1982j~IEEE
Computer Society) Gain settings for each channel were individually adjusted for optimum recorda.ng. The data were stored on videotape for off°line analysis. See P.
~5 Wolf-.'et al., Proc. ACEMB Washington, DC, 12~ (1385).
The recordings from each channel were subsequently displayed on a SUN 3/60 work station to allow measurement _19_ of stimulus potentials and detection of activation times.
Definitions. The ventricular refractory period for a particular strength S2 was defined as the largest S1-S2 interval that failed to evoke a ventricular response. In this study inducible sustained~monomorphic ventricular tachycardia was defined as an ECG sequence of uniform ventricular depolarizations at a cycle length of less than 400 ms, that lasted more than 30 sec or produced hemodynamic compromise requiring immediate a.0 cardloveralon.
Stimulation protocol. Unipolar cathodal pacing at a pulse width of 5 ms was used to determine late diastel3.c threshold at each of the five stimulation sites (two right ventricular sites, two left ventricular sites and the center of the recording plaquej. The propensity for sustained ventricular tachycardia was assessed by pacing at a dycle length of 300 ms for 1.0 beats (Slj at twice diastolic threshold followed by an extra stimulus (S~j consisting of a 5 ms square wave which was given to scan diastole at 5 ms intervals or less: The S~. train was delivered from one of the four pacing sites outside of the plaque of recording electrodes, while S2 was always delivered from the center of the plaque. I?iastole waa scanned by decreasing the S1S2 coupling interval in ~~gpaC.9 of 5 m~'J. ..The. ~,.nltl.al PJtrengthof the S6s ward 10 Stltie I~ diastole was scanned without the induction of ventricular tach~cardia or ventricular gibrillation and the ventricular refractory period was reached, the strength of the 52 was increased by 20 m~, and scanning ~a~s repeated: Once ventricular tachycardia or '" fibrillation was initiated and halted lay cardioversion or degibrillation, the procedure was repeated using a new 51. site with the initial S2 strength set equal to that which induced the arrhythmia at the previous S1 site.
This protocol was repeated at all four S1 sites. After ventricular dysrhythmias were initiated from all four S~
sites, the strength of the S2 was increased in 10 mA
°20-steps to a maximum of 100 mA for one of the S1 pacing sites. -Histoloaical examination. At the end of each experiment, the heart was excised, weighed and fixed in formalin. A histological section was taken perpendicular to the epicardium through the center of the infarct zone beneath the recording plaque to determine the thickness of the infarcted and of the subepicardially spared myocardium. ~n either side of this perpendicular section, serial sections were taken every 0.5 mm parallel to the epicardium in the infarct zone to detenaine fiber orientating of the spared epicardial tissue. All sections were stained with hematoxylin and eosin.
Dataw anal~~sis. The rec~rdings from each channel were displayed on a Sun 3/60 computer, work station. In all. dogs the last two activations of the S1.
traixi and all activations after the S2 stimulus unveil the ventricular tachycardia settled into uniform repeatable complexes on the surface ECG were analyzed. If p ventricular fibrillation instead of ventricular tachycardia was induced, the initial six activation ccam~lexes after the S2 stimulus were chosen far analysis.
the time selected for each activation was the fastest sl~pe for biphasic complexes and the absolute peak value fc~r monophasic and multiphasic compl~xe,~. T. Funada et a~:. , ~?ea. ~ioZ. Erag. Comput. 21, 418 (1980 . Electrodes ~~th saturated signals or with signals too noisy to identify activations reliably were not analyzed.
~gdchronal yaps were drawn for a~.l complexes analyzed.
3~D A heavy black bar was used to indicate block between neighboring electrodes if 1) activation: times differed by more than 40 ms (conduction velocity < 0.1 m/sec), (15-17)'and 2) double activations were seen in the electrodes b~rdering the line of block, in which one complex corresponded in time to the activati~n front on one side of the block and the other complex corresponded to the activation front on the other side of the line of block.
~~.~~u~~
°21-hatched bars were used to represent the '°frame lines"
between sequential isochronal maps. The term "frame line" is used to indicate that the aetivation front does not stop at the line but rather the frame lines represent the break points between maps that are neeessary to represent the dynamic continuous activation sequence of reentry by a series of static discrete isochronal maps.
With voltage dividers (see P. Wolf et al., supra), potentials were measured at the 121 recording 7.0 electrades for 10 ms monophasic shocks equal in strength ~o the lowest current inducing the tachyarrhythmia at all four S1 sites. Potentials were also' recorded for stronger shocks in increments of 2~ mA to a maximum of 1c?0 mA. unipolar potentials were measured at each 25 recording site, relative to the preceding baseline, eat a consistent point 3-4 ms into the shock. A 10 ms stimulus was used to measure the S2 potentials instead of the 5 ms stimulus used for S2 induction of the arrhythmia because a short spike, lasting 1-2 ms, was present in the 2~ recordings at the onset and the offset of the S2 s~imul.us. The potential gradient was calculated from the pbtentials arid the inter-electrode distances using a finite element method. D. Frazier et al., arc. lies. ~3, 14T (1980.
Stati.stical,procedures. Student's t test was used to analyze differences in means. Chi°-square was u~~~ to analyze differences in populati~ns. Data are presented as mean -1 SD. Significance was defined as p50.fl5.
' 3 0 ~~'.BQae'.L'~
,Twelve mongrel dogs weighing 23.5 ~ 1.6 kg were he subj acts of this study. One of the twelve died in the first twelve hours post LAD occlusion. A second dog died four days ~ostinfarction during anesthesia induction 35 for the placement of electrodes. Therefore, arrhythmia induction was attempted in ten animals. In two of the 7 cW', _'~
v U ti :d ten dogs, the S2 threshold for ventricular arrhythmia (sustained ventricular tachycardia or ventricular fibrillation) induction had only been determined for one of the S1 pacing sites before the animals died. In the remaining eight animals, the s2 arrhythmia threshold stimulus was determined for all four S1 pacing sites.
Thus, the S2 arrhythmia threshold stimulus was determined for a total of 34 sites in the ten animals (Tamale 3.) .
Sustained monomorphic ventricular tachycardia was induced from 2~ of these sites, ventricular fibrillation from nine sites and sustained polymorphic ventricular tachycardia was induced from one S1 sate. The episode of polym~rphic ventricular tachycardia was eliminated from all statistical analysis. By chi-square analysis the incidence of monomorphic ventricular tachycardia was significantly different from ventricular fibrillation (p O . t8 3 ~ , T~hE 1 Numb~r,of S1 Sites Imducing Ventricular Tachyarrhythmias dog Humber of Sites Transmural Ptumber ~"~" Extent of ~aah ShIVVT with VF Inarct 1 ~ ~ '70%
2 ~ ~ 70%
2 5 3 4 0 80%
TR~ATMEIVT OF VEIVTRICUU~R TAChiYCARD1A
This invention was made with. Government support under grant numbers HL-28429, FiL-17670, and ~iL-33637 frOa~
the PTational Institutes of Health and grant number CDR-~62~~,~1 fr~yn the National Science Foundation. The Government'ha~ certain rights to this invention.
Field of the Invention This invention relates to methods for the ablation o~ :~s~d~ac tissue for the treatment of vsxatricstlar tachy~arciia and to diagnostic methods for detecting c~nditi~ns which indicate a high risk of ventricular tachycardia.
Rackoround of t#~~ Invent9ora Ventricular tachycardia is a disease of the heart; in whicta the heart's nox~nal rhythaQic contraction is altered, thus affecting heart function. The c~nciition is aften described as a heart beat which is too fast, alti~ough the di ease is far more complexs Ventricular tachycardia occurs most often in patients following a m~rocardial infarction. A myocardial infarction, commonly referred to as a heart attack, is a loss of bl~od flow to a region, of the heart causzng the ~ryocardial .muscle) tissue in that region to die and be replaced by an area ,~2~~~~
_2_ of scar tissue known as a myocardial infarct. In most cases, this occurs in the left ventricle.
Ventricular tachycardia ("VT") may be initiated' and sustained by a re-entrant mechanism, termed a "circus" movement. The mechanism of re-entry, as it is currently understood, is discussed in M. Josephson~and H.
Wellens, Tachycardias: Mechanisms, Diagnosis, Treatment, Chap. 14 (1984)(Lea & Febiger). Most cases of sudden cardiac death that have occurred during cardiac monitoring have begun as VT that degenerated into ventricular fibrillation.
63hile VT can be halted after it begins by pacing or cardioversion, it is preferable to prevent the arrhythmia from arising: Drug therapy has been used, but ~.5 , is successful in only 30 to 50 percent of patients and has undesirable side effects. Endocardial resection, a surgical procedure involving removing the tissue in the ventricle thought to be the source of the VT, has been reported to eradicate VT in up to 90 percent of patients, but a,t suffers from a 5 to 10 percent incidence of per~operata.ve mortalitys For a da.scussion of surg~,cal procedures, see T. Ferguson and J. Cox, Surgical Therapy far Cardiac Arrhythmias, in Nonpharmacological Therapy of Tachyarrhythmias (G: Breithardt et a1. eds. ~.~87).
As an alternative to surgery, the technique most often attempted is ablation. Typically, programmed premature pacing is performed from a catheter electrode ih the right or left ventricular cavity. During prcsgrammed premature pacing, a stimulus, usually of twice diastolic threshold, is repeatedly given prematurely, until either VT is induced or the tissue is too refractory to be excited. The ECG is examined during induced VT and compared to the ECG showing spontaneous bouts of VT. ~f the ECG is similar, it is assumed that 3.5 the patient's clinical VT is being induced. A mapping catheter in the left ventricular cavity is used to record from numerous sites sequentially to determine the _3~
activation sequence along the left ventricular endocardium during the induced VT. The site from which activation appears to originate during the induced VT is identified and assumed to be a portion of the reentrant pathway. The techniques of pace mapping and ~entrainment may then be used in an attempt to confirm or refine the localization of the region rising to VT. The region is then ablated. Unfortunately, this technique is usually unsuccessful unless repeated many times. For example, a.t has been reported by Downer et al. that for a similar -technique (the electrodes were located on an endocardial balloon instead of a catheter) , anywhere from 10 to 42 shocks through different electrodes were required to prevent the reinduction of VT. It is assumed that Z5 failures occur because ablation is not performed at the correct site or does not create a lesion deep enough taithin the ventricular wall to reach the reentrant pathway.
It is extremely desireable to prognose the likelihood of a myocardial infarct patient being susceptible to ventricular tachycardia. U.S. Patent No.
4;680,708 to M. Cain and B. Sobel suggests a method and apparatus for analyzing electrocardiogram signals to progno~e ventricular tachycardia, but the early detection . 25 of myocardial infarct patients susceptible to ventricular tachycardia remains a problem.
In view of the foregoing, an object of the present invention is to provide a technique which is effective in combatting VT, does not require the administration of drugs, and does nut require open°heart surgery.
A further obj ect of the present invention is to provide a means for prognosing the likelihood of ventricular tachycardia occuring in a myocardial infarct patient not previously c~.iagnosed as having ventricular tachycardia: _ . ., . . .. . .. _.:. . _ _ s. .::: ,., ,_, , , .. . _ .
,::..
,:
:.;.
a r e.; ,'. r > :r-i" ., . ":e x .
r i ;'~. . . . . _, . . _ , . , . ..
... .. . _ r. i::. . " . , e.. ~ ~~- . .. . . . ., . . , .. _ . . f , . . ..
", r .... ... . ':. r a :. .:..., ..,. . . .. .. . ... . . , .. , Summary of the Invention The present invention :is based on the concept that a thin layer of viable myocardial tissue adjacent to the endocardium in a myocardial infarct patient is capable of supporting multiple re-entrant pathways, any one of which can give rise to ventricular tachycardia.
In view of the foregoing finding, a first aspect of the present invention is a closed-heart method for treating ventricular tachycardia in a myocardial infarct patient afflicted with ventricular tachycardia.
The method comprises, first, defining a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the endocardium) of the patient, and then ablating the thin layer of spared myocardial tissue by a closed-heart procedure with an ablation catheter.
In a particular embodiment of the foregoing, the ablating step is carried out by creating at least one elongate lesion in said thin layer extending from the endocardium to the myocardial infarct scar tissue in a closed-heart procedure with an ablation catheter. The at least one elongate lesion is configured to reduce the size, in surface area, of any portion of the thin layer in electrical contact with the remainder of the endocardium sufficient to combat ventricular tachycardia in said patient. This may be carried out by electrically separating from the remainder of the endocardium a portion of the thin layer which has a size, in surface area, sufficient to combat ventricular tachycardia (e. g., by creating a continuous elongate lesion around the thin layer of spared myocardial tissue, the continuous lesion encircling the thin layer to electrically separate the thin layer from adjacent myocardial tissue), or by creating at least one (or a plurality) of elongate lesions in the thin layer, wherein the at least one elongate lesion divides the the layer into a plurality of electrically separated portions, with the capability of ' CA 02128892 2001-11-20 spared endocardial tissue connected to the intraventricular catheter, and an analyzing means operatively associated with the detecting means for prognosing the likelihood of ventricular tachycardia arising from the thin layer.
Another aspect of the present invention is an apparatus for ablation treatment of ventricular tachycardia. The apparatus comprises an intraventricular catheter, a detecting means for detecting a thin layer of spared endocardial tissue connected to the intraventricular l0 catheter, and an ablation means for ablating the thin layer of spared endocardial tissue connected to the intraventricular catheter.
Another aspect of the present invention is a method for prognosing the likelihood of ventricular tachycardia occurring in the myocardial infarct patient not previously diagnosed with afflicted with ventricular tachycardia. The method comprises detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the endocardium) in the patient.
In accordance with one embodiment of the present invention, there is provided the use of an apparatus comprises:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
analyzing means operatively associated with said detecting means for determining from the detected boundaries of the thin layer of spared myocardial tissue -5 a-the likelihood of ventricular tachycardia arising from said thin layer; and ablation means for ablating said thin layer of spared myocardial tissue connected to said intraventricular catheter, to treat ventricular tachycardia.
In accordance with another embodiment of the present invention, there is provided the use of an apparatus comprises:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
analyzing means operatively associated with said detecting means for prognosing the likelihood of ventricular tachycardia arising from said thin layer; and ablation means for electrically separating a portion of the thin layer of spared myocardial tissue sufficient in size to combat ventricular tachycardia from the remainder of the myocardium, to treat ventricular tachycardia.
In accordance with another embodiment of the present invention, there is provided a method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium in said 3o patient and determining whether said thin layer of spared myocardial tissue is capable of supporting re-entrant pathways.
~ ' CA 02128892 2001-11-20 -5b-In accordance with another embodiment of the present invention, there is provided a method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium in said patient and determining that the thin layer has a myocardial surface area of at least 15 square centimeters.
In accordance with another embodiment of the present invention, there is provided a method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
creating a map of the locations of the thin layer identified in said determining step to define the layer areas, and evaluating the dimensions of said thin layer areas to determine if the contiguous portions of thin layer areas are of sufficient size to support re-entrant pathways.
In accordance with another embodiment of the present invention, there is provided an apparatus for prognosing the likelihood of ventricular tachycardia in a myocardial infarct patient, the apparatus comprises:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned -Sc-between the myocardial infarct scar tissue and the inner surface of the myocardium; and analyzing means operatively associated with the detecting means for determining from the detected boundaries of the thin layer of spared myocardial tissue the likelihood of ventricular tachycardia arising from said thin layer.
In accordance with another embodiment of the present invention, there is provided an apparatus for prognosing l0 the likelihood of ventricular tachycardia in a myocardial infarct patient, the apparatus comprises:
an intraventricular catheter;
detecting means for detecting the locations of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium; and analyzing means operatively associated with said detecting means for creating a map of the locations of the thin layer detected by the detecting means to define the thin layer areas and evaluating the dimensions of the thin layer areas to determine if the contiguous portions of the thin layer areas are of sufficient size to support re-entrant pathways.
Previous work in the diagnosis and treatment of ventricular tachycardia has always looked for functional or electrical characteristics of tissue rather than a specific anatomic structure. The present invention, in contrast, is based on the finding that a specific macroscopic anatomical structure gives rise to ventricular tachycardia.
~ ' CA 02128892 2001-11-20 -Sd-Brief Description of the Drawings Figure 1 is a side view of a human heart, with portions cut away to reveal the internal chambers and mycardial walls.
Figure 2 illustrates typical cross-sectional slices from control (Fig. 2A), subacute ventricular -s-tachycardia (Fig. 2B), and chronic ventricular tachycardia (Fig. 2C) groups:
Figur~ 3 schematically illustrates various ablation patterns on the internal surface of the heart which may be employed in carrying out the -present invention.
F'ic~ura ~ schematically illustrates an apparatus useful for carrying out the ablation method of the present invention.
20 Figures 5-6 illustrate the use of an apparatus as given in Figure 4.
~'igur~ 7 shows the initiation of sustained ventricular tachycardia settling into a monomorphic figure of 8 reentry pattern. The activation times end isochrc~nal maps of the last beat of the S1 train (Panel A) are shown; as Well as the first 5 beats of VT (Panels ~-F)' 'induced after a 20 mA S2 stimulus at an S1S2 interval of 210 ms as recorded by a plaque of 121 bipolar eledt~°odes over the infarct in the left ventricle. The 511 interval: of the' pacing train is 300 ms. The long axis of the spared myocardial fibers is represented by the double headed arrow at the top of the figure. each number gives the activation time in ms at an electrode sate. The is~chr~nal interval is 20 ms. In panel ~ time 2~ zero ~a the beginr~zng of the S1 stimulus. In Panels B-F
time zero is the beginning of the 52 stimulus. 7Cn panel 8, the first beat after S2 sti~a~lation; arrows indicate that the activation fronts conduct, around both sides of a'line of bl~~k (reepresented by the hea~ay black bar in ~0 ':this and subsequent figures). The hatched line (ia~ this and subsequent figures) represents a frame line between 'panels in which reentry is believed to occur. In panel C; the adjoining solid and hatched lines indicate block between beats one and two and reentry between beats two 35 and three respectively. Panel 2 shows the monomorphic ventricular tachycardia as recorded by the surface leads I, II and ITI. Closed arrow indicates S2.
_~_ F'iguse 8 shows the initiation of sustained monomorphic ventricular tachycardia with a figure of 8 reentry pattern in a second animal in which the S1 was delivered from the tight ventricular free wall. The activation times and isochronal maps of the last beat of the 300 ms S1 train (Panel A) as well as those of the first '3 beats of ventricular tachycardia (Panels B-D) induced by a 30 mA S2 stimulus at an S1S2 interval of 230 ms are shown. In panel E, the activation pattern of the 1.0 first beat post S2 stimulation is compatible with figure of 8 reentry: ~ The initial activation sequence is directed back toward~the S1 stimulation site in the direction opposite the S1 activation sequence. Figure of 8 reentry is also seen in the subsequent beats of ventricular tachycardia (Panels C and D). Panel E shows the lead II rhythm strap of ventricular tachycardia induced. ~pen arrow indicates the first 31 and closed arrow indicates S2. The long axis of the spared myocardial fibers i~ represented by the double headed 20' arrow at the top of the figure.
gigue g shows the initiation of sustained ~noa~omorphic ventricular tachycardia with a figure of 8 reentry pattern in which the S1 was delivered from the left ventricular free wall in the same animal as for Fig.
8. The activation times and isochronal maps, of the last beat of the 30O ms Sl train (Panel A) as well as those of the first 3 beats of ventricular tachycardia (Panels B~D) induced by a 3Q mA S2 stimulus at an S1S2 interval of 230 ms, are shown. In panel B, the activation pattern of the first beat post S2 stimulation is compatible with figure 'of 8 reentry and once again the initial activation is generally back toward the S1 stimulatian site in the diredtion opposite the S1 activation sequence. Figure of 8 reentry is also seen in subsequent beats (Panels C and D). Panel E shows the Lead II rhythm strip of ventricular tachycardia induced. span arrow indicates the first S1 and closed arrow indicates S2.
t r i w ,.. -...-t . i~ .'.
F a S
., n,v..,., ::,4 ~.a t , .. . ,. .. . , a ~~ -' . . . .. . .. < , a .. .. .,. r. . .-i-...n.,.
.n..,.. ... .... .". ... ... .. . .. < . .. ._... . . ..... s.... ._.... .
.v., . . W . , n . .id,i.i.. a , ..ut . ., W W..... r.. .. 5..... ,. .. ..,..
~8_ Detailed Descri tp ion of the invention The basic anatomy 'of the human heart 1~ is illustrated in Figure 1. Its walls are composed primarily of myocardial (muscle) tissue. The muscle tissue walls of the heart are referred to as the myocardium 11. The inner surface of the myocardium, which is in contact with the blood in the heart chambers, is the endocardium 12,12,. The heart is longitudinally divided into left and right halves. Each half has an upper chamber called an atrium 13,14, and a lower chamber called a ventricle ~1~,16. Between the atrium and the ventricle of each half is an atrioventricular (AVM valve 1? which is a one way valve allowing blood flow only from the aarium into the ventricle. The right and left ventricles are separated by the interventricular septum ~~ .
the circulatory system is comprised of two separate systems, pulmonary and systematic circulation.
~n the paal,monary circuit blood is pumped by the right ventricle 15 into the pulmonary artery which then splits info a right pulmonary artery 2~ and a left pulmonary artexy 21 allo~ring t:o flow through the lungs and then info the pulmonary veins 22,23,24,5 which fi~w into the lift atrium 14: The oxygen rich blood from the pulmonary 2~ circuit is pumped by the left ventricle into the systemic circui% via the a~rta. defter passing throughout the body, the blood returns to the right atrium via the inferior vents cave and the superior vane cave, The thic)cness of the walls of the chambers of the hearts vary in relation to the amount of pua~pinc~ worDc they perform. The atria 13, 14 are of little importance in pumping the blood except under high demand conditions, such as exercise, and are thin walled ~2-3 millimeters).
The right ventricle 1~ only pumps blood through the 3~ relativeay short pulmonary circuit and' is significantly more thin walled than the left ventricle 16. which must r .s.r.~..=s. .. . ..... ~ ..:: .,.. .... . . . . . . .:~ : .. .
~~.2~~~~
maintain the pressure within the systemic circuit (8-12 millimeters). -F$c,~ure 2 illustrates typical cross-sectional slices of ventricles from patients with myocardial infarction but no ventricular tachycardia (control, (Fig.
2A), patients with subacute myocardial infarction with ventricular tachycardia (Fig. 2B), and patients with chronic myocardial infarction with ventricular tachycardia (Fig. 2C) groups. The subacute group had predominantly large solid myocardial infarcts 30 with -ribbon spared subendocardium 31. The chronic ventricular tachycardia group has predominantly -large patchy myocardial infarcts 32 with irregular spared subendocardium. The control group had smaller hearts and smaller more randomly distributed patchy myocardial infarcts 34 with little ribbon spared subendocardium 35.
sla~.k represents solid myocardial infarct, and stippling represents patchy myocardial infarct. Slices are seen fr~m the basal aspect. These data are. known. See D.
~Olick et al., Circulation 74, 1266, 1273 (1986).
The thia~ layer referred to herein is a layer of surviving myocardial tissue located between the surface of the endocardiuan 12,12' and the myocardial infarct scar tissue. The thin layer may be in the right or left ventricle, lbut moxe typically the left ventricle. A
layer of fib~°osa.s may be positioned beneath the thin layer, as explained below. WD°iile the precise dimensions ;~f the thin layer will vary from patient to patient; with some va~~.ability due to the variability of the infarct in the epi.cardial to endocardial dimension, tlae thin layer 'Will generally have a thickness of up to about 5 millimeters, and will generally have an endocardial surface area of at least 15 square centimeters.
Typically, the thin layer will have a thickness of from about .25 to 2 millimeters, and will have an endocardial surface area of from about 20 to 40 square centimeters.
~1~~~~~
The present invention is directed to both diagnostic and treatment - methods for ventricular tachycardia in a patient afflicted with a myocardial infarct. The treatment method of the present invention involves first, defining a thin layer ~ of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the endocardium) of the patient, and then ablating the thin layer of spared myocardial tissue. The diagnostic method provides a means for eatamining myocardial infarct patients to determine their risk of developing ventricular tachycardia by detecting the presence of a thin layer of spared myocardial. tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium (the endocardium).
Reentrant pathways causing ~7T may arise from numerous sites within the thin layer of spared tissue between the infarct and the endocardium, the first or defining step involves identifying the presence and 2A location of this thin layer instead of inducing and mapping the activation seeiuence during a particular ~:mcidence of induced 'VT as was done previously. Thus, the subject on which the defining step is performed need ~o.~ have VT induced prior to the procedure, and need not be a;n VT during the deffining step.
The thin layer can be defined by any one or a combination of several techniques, including (1) analyzing rec~rdings during regular rhythm from electrodes on a catheter: (2) pacing from an electrode on 30 the catheter and analyzing the pac~.ng threshold as well 'as recordings of the pacing stimulus and the ensuing activation sequence from other electrc~dcs on the same catheter: (3) direct visualization of the thin layer of spared myocardial tissue by an raging technique such as 3~ echocardiography/ultrasound which can differentiate healthy myocardial tissue from infarc~ed tissue; (4) detecting by echocardiography the infarct itself .;s-..~ t. ~.- ..
,r : ..~,.,_ ~,.
.~
,.
, . . .--: :. - :- , ; . . . . .. ~ . -. ; . a . ..: : .... .
.. . . ..,.. . ... . .. . . . . ..y.. .. ..... .. . ,.. ... ......:: ., . ,..
. ;. . .. .
E
overlying the thin layer of spared myocardial tissue (e. g., by detecting altered heart wall motion overlying the infarct or by detecting altered backscatter from the infarct); (5) visualization of endocardial fibrosis beneath the thin layer of spared myocardial tissue (i.e., between the thin layer of spared myocardial tissue and the ventricular cavity); and (6) electrically stimulating the endocardium to detect an increased -pacing threshold (due to the presence of endocardial fibrosis overlying the thin layer of spared myocardial tissue).
Any suitable apparatus may be employed to carry out the defining step, such as a catheter .mounted echocardiographic ultrasound crystal sensor inserted into the interior of the. heart of said patient, an echocardiographic ultrasound crystal sensor positioned in 'the esophagus of the patient, or echocardiographyic u~,txa~ound crystal sensor applied to the chest wall by contact to the skin. The imaging device need not be on catheter. (is in the case of an esophageal 2d echoc~rdiograph); though preferably the mapping is performed with a catheter mounted sensing device.
Particularly suitable is an echocardiagraphic,ultrasound crystal. sensor mounted on a catheter whiclh is inserted iz~tb the interior ~f the heart of the patient. This sane ca~tJheter can also carry the ablation device as discussed be3.ow: Suitably detection devices are known, examples of Which are disc~:OSed in U.S. Pat. N0. 5,Oa0,185 and in PCT
Application Nt~mb~r i~0 91/0288. (Applicants intend that all U:S. Patent references cited herein be incorporated herein by reference). An ultrasonic technnque,, for.
capping myocardial tissue with an external sensor is discussed In ~ s ~ar~llal et al s , ~o rlJl6e ~~~r . SICTI6d a ~, 17~-186 (~.~88)(showing altered backscatter from myocardial infarct).
Once the thin layer of spared myocardium is identified, it can be ablated by a variety of methods.
Three such methods of the present invention, along with prior art methods, are schematically illustrated in Figur~ 3. The endocardial- surface is schematically illustrated in Fig. 3A, the prior art surgical resection technique is illustrated ~in Fig. 38, and prior art catheter ablation techniques are sc~aematically .
of the illustrated in Fig. 3C. In the embodiment invention illustrated in Fig. ~D, ablation is accomplished by creating a continuous lesion ~l extending from the endocardiu~ to the myocardial infarct scar tissue around the thin layer of spared myocardial tissue.
This Continuous lesion encircling the thin layer electrically isolates the thin layer from adjacent myocardial tissue so that any arrhythmias arising in the thin layer are not able to propagate into the rest of the heart. In the embodiment of the invention illustrated. in Fig. 3E, ablation is accomplished by creating at least one, ~r as illustrated a plurality of, elongate lesions ~~ ~.r~ the thin layer, with each lesion extending from the endocardium to the myocardial infarct scar tissue. The elongate lesi~n (s) are patterned to divide the thin layer fnto a plurality of electrically separated portions each, of which is substantially incapable of originating ventricular tachycardia. In the embodiment of, the inven~.ion illustrated in Fig: 3F, ablation is accomplished by destroying all of the thin layer of sp~.red myocardial issue with a large lesion ~3.
~A Vara.ety of devices ars known and available for performincj the ablation step: A. direct current ablation electrode such as that disclosed in tl.S. Pat.
No: x,896,671 csr a laser ablation catheter such as that disclosed' 1r~ U:S. Pat. No. 4,985,028 may be u~~d. More preferably, a radib frequency (RF) ablati~n catheter as disclosed in U:S: Pat. No. 4,945,91 or a microwave ablation catheter such as that discussed in J. Langberg et al.., Pace 1~, 2105 (December, 1991) is used. Another approach is to ablate the thin layer with ultrasound at high energy, as discussed in greater detail below.
_....... _.._ z. . .. . . .. . .. .. , .. .,.~,~. , .. . , . . .., ra . ~'f.' ... ...... . ,..,... , ~~2gb9~
As noted above, both the detecting means such as an echocardiagraphic/ultrasound crystal sensor and an ablation means such as a laser unit may advantageously be located-on the same catheter. Examples of such catheter devices are disclosed in U.S. Pat. No. 5,000,185, U.S.
Pat. No. 4,936,281 and in PCT Application Number WO
91/02488. A schematic diagram of such a catheter device using and ultrasound sensing means and a laser ablation means is shown in Figur~ 4. The system 5a includes a l0 catheter probe assembly 51 including a distal subassembly 52 inserted within a guide catheter 53. The proximal end of the guide catheter 53 is coupled to a conventional side arm connector 54. The distal subassembly 52 is coupled to a suitable motor means 55 which provides the d~~.ve to maneuver the distal subassembly 52. The ultrasonic imaging components within the distal subassembly 52 are electrically connected with an electroacoustic transducer and an ultrasound transceiver 5~ via suitable electrical contact brushes 57. To perform detection the ultrasonic imaging coMponents wa:thin the distal subassembly are activated and the received signals are processed by the ultrasound transceiver 5fs. The signals are further processed by algorithms gerfor~ed by the computer 5~ to generate an a.mage of the tissue structures reflecting the ultrasonic energy toward the distal subassembly 52. The ablating is ~aerf~rmed by a laser means. A laser driver 60 provides a source of ~.aser radiation which passes via the contact brushes 57 to a dual function eiectrical/optical ~0 c~nnector 6i which couples tlae ultrasonic ianaging components and laser optical components within the distal subassembly 52 to the ultrasound transceiver 55 and the laser driver ~0. The computer 5~ also functions to allow the operator to control the laser driver to perform ablation of tissue where desired.
A software program running in the computer 5~, which computer is operatively associated with the ~1~~~~~, detecting means, provides a means for prognosing the likelihood of ventricular tachycardia arising from said thin layer. In a typical embodiment of this method, the detecting step includes determining if a thin layer of spared tissue exists between the infarct scar tissue and the endocardium, then creating an anatomical map of the locations of the thin layer identified to define the thin layer areas, .and then evaluating the dimensions of the thin layer areas to determine if the contiguous portions e~f these areas are of sufficient size to support reentrant pathways.
Another option in an apparatus of the present invention is, as noted above, to use ultrasound energy at higher power lwels to ablate the thin layer of tissue.
An intraven~cricular catheter for accomplishing ,this method w~uld have two sets of ultrasound crystal connected thereto: one set configured for detecting the ~p~in layer, arid another set configured for ablation of the thin layer:
Figures 5-6 illustrate the use of a catheter of Fa.gw 4 ire a method of the present invention. The catheter 5l is first introduced into the circulatory .system, preferably through a vessel in the leg, and advanced into the heart l0. In the typical case of a ~5 patient suffering from VT follawing a myocardial i~farctzan, the infarct scar tissue is located in the lift ven~r~.cle l6,' either within the outer walls of the ventricle or within the interventricular septum 3.~. In such a patient, the catheter is advanced into the left 30 ventricle 16, for example by advancing the catheter into ' the femoral artery and then through the aorta ~6 into the left ventricle l~. The detecting means is then activated and the catheter is manipulated substantially throughout the left ventricle l6 to locate any areas of thin layers 35 of sua-viving tissue between the endocardium ~2 and the infarct scar tissue. Preferably, this information is r~'.~~'i~- :r~J z. ~i:,.,J'.. $4f ~~..~~,~"5 . ..........,... ,.~. ........ .. .., .s". .. " ...,.., ...;..l..
L.~..sdsPl9~'.'an. .., .. :','::Z'r:'1'~: ., ,/.r..".....~.lo-..t,.. N.
",...rvn.. v...n.ei....:. f......l.,.f~M',p.~°~l~.o..,... ,.... .... .
. a.. ,..
~~2~~~'~
~~~~
generated for substantially the entire area affected and then the catheter is withdrawn.
In the treatment of the present invention, each thin layer area located is rendered substantially incapable of supporting VT by the ablating step. The ablating step may be performed for alI the thin layer areas found after the mapping is completed or, more preferably, is performed on each contiguous thin layer area once the area is defined. The portions of tissue to be ablated depends upon the embodiment of the present invention utilized~as was discussed previously.
The ablating step is optionally followed by the step of verifying that the thin layer of spared myocardial. tissue is no longer capable of originating a ventricular tachycardia. This verifying step can be accomplished msing a programmed pacing technique to induce ventricular tachycardia. Such techniques are discussed in M: Josephson and H. wellens, Tachycardias:
Mechanisms, Diagnosis, Treatment, Chap. l4, X1984).
As noted above, the present invention further provides a method for prognosing the likelihood of ventricular tachycardia occuring in a myocardial infarct patient not previously diagnosed as afflicted with uentricul~r ta~hycardia. The method comprises detecting a thin layer ;of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner ~uxface of the myocardium the endocardium) in the P~'~icn'~. The thin layer to be detected is described in detail above: The procedure is advantageously carried.
out by closed-heart procedures, as discussed in, detail above. ~ ~n a typical embodiment of this method, the detecting step includes determining if a thin layer of spared tissue exists between the infarct scar tissue and the endocardium, then creating an ana~ramical map of the locations of the thin layer identified to define the than layer areas, and then evaluating the dimensions of the thin layer areas to determine if the contiguous portions ;o r ,~
-ls_ .
of these areas are of sufficient site to support reentrant pathways.
The present invention is explained further in the following Example. This Example is illustrative of the present invention, and is not to be construed as limiting thereof.
high current Stimuli to the Spared Ep cardium of a ~arg~ ~Cmfmret gnduc~ ~entricular Ta~chycardia This study was carried out to test the hypothesis that a high current premature stimu3.us during the vulnerable period over the surviving epicardium of a f~ur day old infarct in a canine model will induce sustained V'.C' rather than ventricular fibrillation. As explained in detail below, it Was found that a large S2 over ~a nontransmural infarct induced VT if the spared myocardium was thin> .
1~'fERI~Ir~ ~1'D ~IE'g!H~DS
Surgical ureparation. In twelve mongrel dogs, anesthesia was induced using intravenous thiopental sodium, 20 mgfkg, and maintained using a continuous ~.nfusi.~n of thiopental sodium at a maintenance rate of ,appr~ximately 0, 8 angfkg/min. Succinylch~line, 1 mgJ~cg, was also given at the time of anesthesia induction. The animals were incubated with a cuffed: endotracheal tube and ventilated with room air and oxygen thr~u~h a Harvard respirator (Harvard Apparatus ~o. South Id~~i.~k; MA): A
~~m~ral arterial Tine and two ~:ntr~ven~us lines were insex~edl using sterile technic~aaes. Syst~i~ic agterial 0 pressure was continuously displayed. Arterial blood samples were drawn every 30°60 min for determa.nation of pH, PA2, Pe02, base excess, bicarbonate, ~a~', K'', and ~a~'' content. Ringer°s lactate was~continuously infused via a peripheral intravenous line. This was supplemented 35 with sodium bicarbonate, potassium~chloride, and calcium ,=..l ~ , .
,.:
'.. f P.~ ::..
o-.~y. ..
.. f'.:
.. h t 0. !.
~ n . n, .
W.,v:
r , 1;,.u r I. 4 , H
o . . , ..u, ~ . . . , n . . , . . . _ 1 . . ... ~ , . . . ,. , .. .. , ....,......,...,... . .. . , ,. . .J,~fi-:° . ." .._.. r. . ..
i:.:m , .., ......,., ,.... .. ,.. .",.. .... n. .. . ..
21~~~~~
_1,_ chloride as indicated to maintain pH and electrolytes within normal values. Electrocardiographic leads were applied for continuous ECG monitoring. Eody temperature was maintained with a thermal mattress. With sterile surgical techniques the heart was exposed through a left thoracotomy at the fourth intercostal space; the pericardium was opened, and the left anterior descending coronary (hAD) artery was dissected free at the tip of the left atrial appendage. A noose occluder was placed around the left anterior descending artery and it was occluded by the Harris two state procedure (A. Harris and A. Rojas, Exp. Med. Sung. l, 105 (1943)). In order to ensure sparing of the epicardium in the entire infarct zone, partial occlusion was maintained for 30 min, followed by complete occlusion for 90 min prior to reperfusion. Five minutes before initiation of partial occlusion and again before the terma.nation of complete occlusion the- animals were pre-treated with bolus alnjections of intravenous lidocaine (2 mg/kg). A second bales of lidocaine (1 mg/kg) was administered ten minutes latex. The chest was closed in layers, evacuated under negative pressure and the animal was allowed to recover.
Four'days after LAD occlusion, anesthesia was , induced with intravenous pentobarbital (30-35 mg/kg body ~5 w~:fight) and maintained with a continuous infusion of pent~barbital at a rate of approximately 0.05 mg/kg per min guccinylcholine (1 mg/kg) Haas also given intravenously, at the time of anesthesia induction.
S~Qplemental doses of 0.25 of 0.5 mg/kg of 3A ~uccinylcholin~ were given hourly as needed to r~a~.r~tain meascle re~.ax~tion. The animals were ventilated, hemodynamically monitored and maintained as described above. A median sternotomy was performed, and the heart was suspended in a pericardial cradle. The recording 35 apparatus consisted of 121 bipolar Ag-AgCI epicardial electrodes (see F. Witkowski and P. Penkoske, Am. J.
Phys~ol. 254, H804 (1988)) arranged in 11. columns and 11 _1g_ rows mounted in a 4X4 cm plaque. Each epicardial electrode was 1 mm in diameter. There was a 2 mm intra-electrode distance between eaeh member of the bipolar pair and an inter-electrode distance of 4 mm. This plaque also contained a centrally located stimulating electrode. The plaque of epicardial recording electrodes was sutured ~ver the infarcted anterior surface of the left ventricle. Four solid stainless steel wires t:~terican Wire Gauge # 30, Cooper Wire Co. Chatsworth, CA) that were insulated except at the tip were positioned for S3 pacing from the lateral right ventricle, the right ventricular outflow tract, the lateral left ventricle seed the posterior left ~rentricle. Defibrillating patches mere sutured over the right atrium and upper portion of the lateral right ventricle and the posterior apical left ventricle to deliver cardioversion or defibrillation shocks. Limb leads I, II and III were recorded with limb lewd IT filtered from 50 Hz to 300 Hz so it recovered quickly after'large premature stimuli.
Data ~cc~u~.sition. A computer assisted-mapping system capable of simultaneously recording 128 channels was used to record the stimulus potentials in unipolar mode with the left leg as reference and the activation complexes in bipolar mode. See P. Wolf ~t al., ~r Method of Measuring Cardiac Defibrillation Potentials, Pros.
~CEM.S Ealtimore; Md., 4 t1986)(The Alliance for Engineering in Medicine and biology, Publishers).
Signals were redorded digitally at a rate of 1,000 samples per second with a low gees filter at 500 Hz and . the high-pass filter at 5 Hz. See W. Smith et al., ~Pxoceedings cg computers in cardiology, 1~1 ~1982j~IEEE
Computer Society) Gain settings for each channel were individually adjusted for optimum recorda.ng. The data were stored on videotape for off°line analysis. See P.
~5 Wolf-.'et al., Proc. ACEMB Washington, DC, 12~ (1385).
The recordings from each channel were subsequently displayed on a SUN 3/60 work station to allow measurement _19_ of stimulus potentials and detection of activation times.
Definitions. The ventricular refractory period for a particular strength S2 was defined as the largest S1-S2 interval that failed to evoke a ventricular response. In this study inducible sustained~monomorphic ventricular tachycardia was defined as an ECG sequence of uniform ventricular depolarizations at a cycle length of less than 400 ms, that lasted more than 30 sec or produced hemodynamic compromise requiring immediate a.0 cardloveralon.
Stimulation protocol. Unipolar cathodal pacing at a pulse width of 5 ms was used to determine late diastel3.c threshold at each of the five stimulation sites (two right ventricular sites, two left ventricular sites and the center of the recording plaquej. The propensity for sustained ventricular tachycardia was assessed by pacing at a dycle length of 300 ms for 1.0 beats (Slj at twice diastolic threshold followed by an extra stimulus (S~j consisting of a 5 ms square wave which was given to scan diastole at 5 ms intervals or less: The S~. train was delivered from one of the four pacing sites outside of the plaque of recording electrodes, while S2 was always delivered from the center of the plaque. I?iastole waa scanned by decreasing the S1S2 coupling interval in ~~gpaC.9 of 5 m~'J. ..The. ~,.nltl.al PJtrengthof the S6s ward 10 Stltie I~ diastole was scanned without the induction of ventricular tach~cardia or ventricular gibrillation and the ventricular refractory period was reached, the strength of the 52 was increased by 20 m~, and scanning ~a~s repeated: Once ventricular tachycardia or '" fibrillation was initiated and halted lay cardioversion or degibrillation, the procedure was repeated using a new 51. site with the initial S2 strength set equal to that which induced the arrhythmia at the previous S1 site.
This protocol was repeated at all four S1 sites. After ventricular dysrhythmias were initiated from all four S~
sites, the strength of the S2 was increased in 10 mA
°20-steps to a maximum of 100 mA for one of the S1 pacing sites. -Histoloaical examination. At the end of each experiment, the heart was excised, weighed and fixed in formalin. A histological section was taken perpendicular to the epicardium through the center of the infarct zone beneath the recording plaque to determine the thickness of the infarcted and of the subepicardially spared myocardium. ~n either side of this perpendicular section, serial sections were taken every 0.5 mm parallel to the epicardium in the infarct zone to detenaine fiber orientating of the spared epicardial tissue. All sections were stained with hematoxylin and eosin.
Dataw anal~~sis. The rec~rdings from each channel were displayed on a Sun 3/60 computer, work station. In all. dogs the last two activations of the S1.
traixi and all activations after the S2 stimulus unveil the ventricular tachycardia settled into uniform repeatable complexes on the surface ECG were analyzed. If p ventricular fibrillation instead of ventricular tachycardia was induced, the initial six activation ccam~lexes after the S2 stimulus were chosen far analysis.
the time selected for each activation was the fastest sl~pe for biphasic complexes and the absolute peak value fc~r monophasic and multiphasic compl~xe,~. T. Funada et a~:. , ~?ea. ~ioZ. Erag. Comput. 21, 418 (1980 . Electrodes ~~th saturated signals or with signals too noisy to identify activations reliably were not analyzed.
~gdchronal yaps were drawn for a~.l complexes analyzed.
3~D A heavy black bar was used to indicate block between neighboring electrodes if 1) activation: times differed by more than 40 ms (conduction velocity < 0.1 m/sec), (15-17)'and 2) double activations were seen in the electrodes b~rdering the line of block, in which one complex corresponded in time to the activati~n front on one side of the block and the other complex corresponded to the activation front on the other side of the line of block.
~~.~~u~~
°21-hatched bars were used to represent the '°frame lines"
between sequential isochronal maps. The term "frame line" is used to indicate that the aetivation front does not stop at the line but rather the frame lines represent the break points between maps that are neeessary to represent the dynamic continuous activation sequence of reentry by a series of static discrete isochronal maps.
With voltage dividers (see P. Wolf et al., supra), potentials were measured at the 121 recording 7.0 electrades for 10 ms monophasic shocks equal in strength ~o the lowest current inducing the tachyarrhythmia at all four S1 sites. Potentials were also' recorded for stronger shocks in increments of 2~ mA to a maximum of 1c?0 mA. unipolar potentials were measured at each 25 recording site, relative to the preceding baseline, eat a consistent point 3-4 ms into the shock. A 10 ms stimulus was used to measure the S2 potentials instead of the 5 ms stimulus used for S2 induction of the arrhythmia because a short spike, lasting 1-2 ms, was present in the 2~ recordings at the onset and the offset of the S2 s~imul.us. The potential gradient was calculated from the pbtentials arid the inter-electrode distances using a finite element method. D. Frazier et al., arc. lies. ~3, 14T (1980.
Stati.stical,procedures. Student's t test was used to analyze differences in means. Chi°-square was u~~~ to analyze differences in populati~ns. Data are presented as mean -1 SD. Significance was defined as p50.fl5.
' 3 0 ~~'.BQae'.L'~
,Twelve mongrel dogs weighing 23.5 ~ 1.6 kg were he subj acts of this study. One of the twelve died in the first twelve hours post LAD occlusion. A second dog died four days ~ostinfarction during anesthesia induction 35 for the placement of electrodes. Therefore, arrhythmia induction was attempted in ten animals. In two of the 7 cW', _'~
v U ti :d ten dogs, the S2 threshold for ventricular arrhythmia (sustained ventricular tachycardia or ventricular fibrillation) induction had only been determined for one of the S1 pacing sites before the animals died. In the remaining eight animals, the s2 arrhythmia threshold stimulus was determined for all four S1 pacing sites.
Thus, the S2 arrhythmia threshold stimulus was determined for a total of 34 sites in the ten animals (Tamale 3.) .
Sustained monomorphic ventricular tachycardia was induced from 2~ of these sites, ventricular fibrillation from nine sites and sustained polymorphic ventricular tachycardia was induced from one S1 sate. The episode of polym~rphic ventricular tachycardia was eliminated from all statistical analysis. By chi-square analysis the incidence of monomorphic ventricular tachycardia was significantly different from ventricular fibrillation (p O . t8 3 ~ , T~hE 1 Numb~r,of S1 Sites Imducing Ventricular Tachyarrhythmias dog Humber of Sites Transmural Ptumber ~"~" Extent of ~aah ShIVVT with VF Inarct 1 ~ ~ '70%
2 ~ ~ 70%
2 5 3 4 0 80%
4 4 ~ 80%
54 l 0 ~0%
S 3 2 80%
~ 2+ 1 80%
8 2 2 30%
9 0 4 20% I
ao" o ~ ~.o%
' Died after first arrhythmic went Polymorphic VT from an additional S1 site 3 5 5MVT = Monomorphic Sustained Ventricular Tachycardia VF = Ventricular Fibrillation 2~~28~92 Figure 7 shows an example of monomorphic ventricular tachycardia induced in a dog with an ~0~
transmural infarct. The S1 pacing site was the right ventricular free wall and the S2 stimulus was 20 mA, which is the lowest strength S2 stimulus that induced tachycardia in this animal. The activation front initiated by S1 stimulation enters from the upper left corner which is the area closest to the S1 pacing site (Fig. 7~1) . The front then conducts diagonally across the tissue under the plague, following the long axis of the myocardial fibers. The earliest activations after S2 stimulation are recorded on the left side of the plaque toward the Sl site (~'ig. 7B), which is more recovered than the right and bottom sides at the time of S2 stimulation. The activation fronts then conduct to the right around both sides of a line of block (represented by fihe heavy black bay). There is a 71 ms time difference between the latest activation time recorded in the initial ventricular tachycardia beat (Fig. ?B) and the earliest activation time recorded in the next beat (gig~ 7C) and double complexes are recorded at these sites: Therefore; block is assumed present between the late site in Figure 7B and the adjacent early sites in Fic~us~ 7C; so that i~t is not clear how ~r if the first beat conducted to the second. The fact that earliest activation sates for the second ventricular tachycardia ~ea,$. are not' at the edge of the plaque as for the first beau, but aye next to the line of assumed block, raises the possibility that reentry did occur, although it was undetected in the recordings. Activation then sweeps around the upper line of block and possibly sweeps also around the lower line of block although this is not definite because the lower line of block extends to the edge of the plague (Fig. 7C). The latest activation tine 3~ in this beat is 31 ms before the earliest activation time recorded in the third tachycardia beat (Fig. 9D) and double complexes are no longer observed in this region.
-24°
Thus reentry is assumed to occur between these two beats.
The central line in Figure 7C is shown solid to the left and hatched to the right to represent block between beats 1 (Fig. 7H) and 2 (Fig. 7C) and reentry between beats 2 (Fig. 7C) and 3 (Fig. 7D). The hatched line is a frame line between successive panels that is necessary to represent reentry by a series of isochronal maps. A
similar activation pattern is seen for the next three beats (Fig. ?D-F) with slight changes in the lines of block from beat to beat. By the fifth beat, the lower line of block has shortened, so that a clear figure of reentry pattern is present (Fig. 7F). The tachycardia was stable after the fifth beat with only minimal changes in the frame and block lines in subsequent activation sec~xences. Conduction through the isthmus stabilized after the seventh beat:
. Iri ~.~ of the 3~ episodes of ventricular t~~hyarrhythmias induced by stimulation from the various ~1 jpacing sites, it was possible to identify the initial activation sites of the first beat of the arrhythmia.
Earliest post S2 activation was never recorded from the regi.orz immediately adjacent to the S2 electrode. In 14 of these 19 episodes initial activation occurred somewhere between the Sl and the S2 stimulation site and generally conducted in the direction away from the S2 electrode and towards the S1 electrode, in the opposite direction to the Sl activation sequence (Fig. H, 9). In the other 5 episodes the initial post S2 activation of the arrhythmia seemed to conduct into the recording area from outside the plaque (Fig. 7~). In the remaining 'arrhythmia episodes, the initial activation sites of the first arrhythmia beat could not be identified because of post S2 stimulation saturation 4f a large percentage of the recording electrodes. However, by the second beat it Gould be identified that the activation front was in the opposite direction of the S1 activation sequence in 25 of the 33 arrhythmia episodes.
a °25-Comparison of Ventricular Tachvcardia and Fibrillation Induction. ~ Sustained monomorphic ventricular tachycardia was the only arrhythmia induced in five dogs. In these animals, the mean transmural infarct extent was SQ% (Table 1). Ventricular fibrillation was the only arrhytr~nia induced in two dogs.
In these animals, the mean transmural extent of the infarct was 15%. Both ventricular tachycardia and fibrillation were induced in three dogs where the transmural extent of the infarct was 63%.
Coinclusions. These data show that the more transmural the infarct and the thinner the layer of spared epicardial tissue, the more likely the figure of 8 reentry pattern will have a longer cycle length and 5 result in ventricular tachycardia rather than ventricular fibrillation.
The foregoing examples are illustrati~re of the present invention; and are not to be construed as ~~:mxti.x~g there~f . The insrention is defined by the 1C following claims, with equivalents of the claims to be included therein. .
.; .
.. ...., . ,...... ..... .......~. ..... ...... x ... ......~ ., ,. . ,. ,.
54 l 0 ~0%
S 3 2 80%
~ 2+ 1 80%
8 2 2 30%
9 0 4 20% I
ao" o ~ ~.o%
' Died after first arrhythmic went Polymorphic VT from an additional S1 site 3 5 5MVT = Monomorphic Sustained Ventricular Tachycardia VF = Ventricular Fibrillation 2~~28~92 Figure 7 shows an example of monomorphic ventricular tachycardia induced in a dog with an ~0~
transmural infarct. The S1 pacing site was the right ventricular free wall and the S2 stimulus was 20 mA, which is the lowest strength S2 stimulus that induced tachycardia in this animal. The activation front initiated by S1 stimulation enters from the upper left corner which is the area closest to the S1 pacing site (Fig. 7~1) . The front then conducts diagonally across the tissue under the plague, following the long axis of the myocardial fibers. The earliest activations after S2 stimulation are recorded on the left side of the plaque toward the Sl site (~'ig. 7B), which is more recovered than the right and bottom sides at the time of S2 stimulation. The activation fronts then conduct to the right around both sides of a line of block (represented by fihe heavy black bay). There is a 71 ms time difference between the latest activation time recorded in the initial ventricular tachycardia beat (Fig. ?B) and the earliest activation time recorded in the next beat (gig~ 7C) and double complexes are recorded at these sites: Therefore; block is assumed present between the late site in Figure 7B and the adjacent early sites in Fic~us~ 7C; so that i~t is not clear how ~r if the first beat conducted to the second. The fact that earliest activation sates for the second ventricular tachycardia ~ea,$. are not' at the edge of the plaque as for the first beau, but aye next to the line of assumed block, raises the possibility that reentry did occur, although it was undetected in the recordings. Activation then sweeps around the upper line of block and possibly sweeps also around the lower line of block although this is not definite because the lower line of block extends to the edge of the plague (Fig. 7C). The latest activation tine 3~ in this beat is 31 ms before the earliest activation time recorded in the third tachycardia beat (Fig. 9D) and double complexes are no longer observed in this region.
-24°
Thus reentry is assumed to occur between these two beats.
The central line in Figure 7C is shown solid to the left and hatched to the right to represent block between beats 1 (Fig. 7H) and 2 (Fig. 7C) and reentry between beats 2 (Fig. 7C) and 3 (Fig. 7D). The hatched line is a frame line between successive panels that is necessary to represent reentry by a series of isochronal maps. A
similar activation pattern is seen for the next three beats (Fig. ?D-F) with slight changes in the lines of block from beat to beat. By the fifth beat, the lower line of block has shortened, so that a clear figure of reentry pattern is present (Fig. 7F). The tachycardia was stable after the fifth beat with only minimal changes in the frame and block lines in subsequent activation sec~xences. Conduction through the isthmus stabilized after the seventh beat:
. Iri ~.~ of the 3~ episodes of ventricular t~~hyarrhythmias induced by stimulation from the various ~1 jpacing sites, it was possible to identify the initial activation sites of the first beat of the arrhythmia.
Earliest post S2 activation was never recorded from the regi.orz immediately adjacent to the S2 electrode. In 14 of these 19 episodes initial activation occurred somewhere between the Sl and the S2 stimulation site and generally conducted in the direction away from the S2 electrode and towards the S1 electrode, in the opposite direction to the Sl activation sequence (Fig. H, 9). In the other 5 episodes the initial post S2 activation of the arrhythmia seemed to conduct into the recording area from outside the plaque (Fig. 7~). In the remaining 'arrhythmia episodes, the initial activation sites of the first arrhythmia beat could not be identified because of post S2 stimulation saturation 4f a large percentage of the recording electrodes. However, by the second beat it Gould be identified that the activation front was in the opposite direction of the S1 activation sequence in 25 of the 33 arrhythmia episodes.
a °25-Comparison of Ventricular Tachvcardia and Fibrillation Induction. ~ Sustained monomorphic ventricular tachycardia was the only arrhythmia induced in five dogs. In these animals, the mean transmural infarct extent was SQ% (Table 1). Ventricular fibrillation was the only arrhytr~nia induced in two dogs.
In these animals, the mean transmural extent of the infarct was 15%. Both ventricular tachycardia and fibrillation were induced in three dogs where the transmural extent of the infarct was 63%.
Coinclusions. These data show that the more transmural the infarct and the thinner the layer of spared epicardial tissue, the more likely the figure of 8 reentry pattern will have a longer cycle length and 5 result in ventricular tachycardia rather than ventricular fibrillation.
The foregoing examples are illustrati~re of the present invention; and are not to be construed as ~~:mxti.x~g there~f . The insrention is defined by the 1C following claims, with equivalents of the claims to be included therein. .
.; .
.. ...., . ,...... ..... .......~. ..... ...... x ... ......~ ., ,. . ,. ,.
Claims (20)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. Use of an apparatus comprising:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
analyzing means operatively associated with said detecting means for determining from the detected boundaries of the thin layer of spared myocardial tissue the likelihood of ventricular tachycardia arising from said thin layer; and ablation means for ablating said thin layer of spared myocardial tissue connected to said intraventricular catheter, to treat ventricular tachycardia.
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
analyzing means operatively associated with said detecting means for determining from the detected boundaries of the thin layer of spared myocardial tissue the likelihood of ventricular tachycardia arising from said thin layer; and ablation means for ablating said thin layer of spared myocardial tissue connected to said intraventricular catheter, to treat ventricular tachycardia.
2. Use of an apparatus in accordance with claim 1 wherein the thin layer has a thickness of up to about 5 millimeters.
3. Use of an apparatus in accordance with claim 1 wherein the thin layer has a thickness of from about 0.25 to 2 millimeters.
4. Use of an apparatus in accordance with claim 1 wherein the thin layer has an myocardial surface area of at least 15 square centimeters.
5. Use of an apparatus in accordance with claim 1 wherein the thin layer has an myocardial surface area of from about 20 to 40 square centimeters.
6. Use of an apparatus in accordance with claim 1 wherein the apparatus is used in the absence of ventricular tachycardia.
7. Use of an apparatus comprising:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
analyzing means operatively associated with said detecting means for prognosing the likelihood of ventricular tachycardia arising from said thin layer; and ablation means for electrically separating a portion of the thin layer of spared myocardial tissue sufficient in size to combat ventricular tachycardia from the remainder of the myocardium, to treat ventricular tachycardia.
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
analyzing means operatively associated with said detecting means for prognosing the likelihood of ventricular tachycardia arising from said thin layer; and ablation means for electrically separating a portion of the thin layer of spared myocardial tissue sufficient in size to combat ventricular tachycardia from the remainder of the myocardium, to treat ventricular tachycardia.
8. A method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium in said patient and determining whether said thin layer of spared myocardial tissue is capable of supporting re-entrant pathways.
9. A method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium in said patient and determining that the thin layer has a myocardial surface area of at least 15 square centimeters.
10. A method according to claim 8 or 9, wherein said method is a closed-heart method.
11. A method for prognosing the likelihood of ventricular tachycardia occurring in a myocardial infarct patient not previously diagnosed as afflicted with ventricular tachycardia, said method comprising detecting a thin layer of spared myocardial tissue positioned between the myocardial infarct scar tissue and the inner surface of the myocardium;
creating a map of the locations of the thin layer identified in said determining step to define the layer areas, and evaluating the dimensions of said thin layer areas to determine if the contiguous portions of thin layer areas are of sufficient size to support re-entrant pathways.
creating a map of the locations of the thin layer identified in said determining step to define the layer areas, and evaluating the dimensions of said thin layer areas to determine if the contiguous portions of thin layer areas are of sufficient size to support re-entrant pathways.
12. A method according to claim 9, wherein said detecting step comprises the step of detecting a thin layer having a myocardial surface area of from about 20 to 40 square centimeters.
13. An apparatus for prognosing the likelihood of ventricular tachycardia in a myocardial infarct patient, the apparatus comprising:
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium; and analyzing means operatively associated with the detecting means for determining from the detected boundaries of the thin layer of spared myocardial tissue the likelihood of ventricular tachycardia arising from said thin layer.
an intraventricular catheter;
detecting means for detecting the boundaries of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium; and analyzing means operatively associated with the detecting means for determining from the detected boundaries of the thin layer of spared myocardial tissue the likelihood of ventricular tachycardia arising from said thin layer.
14. The apparatus of claim 13 wherein the analyzing means determines from the detected boundaries of the thin layer of spared myocardial tissue if the thin layer is capable of supporting re-entrant pathways which can give rise to ventricular tachycardia.
15. The apparatus of claim 13 wherein the analyzing means determines from the detected boundaries of the thin layer of spared myocardial tissue if the thin layer has a surface area of at least 15 square centimeters.
16. An apparatus for prognosing the likelihood of ventricular tachycardia in a myocardial infarct patient, the apparatus comprising:
an intraventricular catheter;
detecting means for detecting the locations of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium; and analyzing means operatively associated with said detecting means for creating a map of the locations of the thin layer detected by the detecting means to define the thin layer areas and evaluating the dimensions of the thin layer areas to determine if the contiguous portions of the thin layer areas are of sufficient size to support re-entrant pathways.
an intraventricular catheter;
detecting means for detecting the locations of a thin layer of spared myocardial tissue connected to said intraventricular catheter, the thin layer being positioned between the myocardial infarct scar tissue and the inner surface of the myocardium; and analyzing means operatively associated with said detecting means for creating a map of the locations of the thin layer detected by the detecting means to define the thin layer areas and evaluating the dimensions of the thin layer areas to determine if the contiguous portions of the thin layer areas are of sufficient size to support re-entrant pathways.
17. The apparatus of any one of claims 13 to 16 further comprising:
ablation means for ablating said thin layer of spared myocardial tissue.
ablation means for ablating said thin layer of spared myocardial tissue.
18. The apparatus of any one of claims 13 to 17 wherein the detecting means comprises an echocardiographic detecting means.
19. The apparatus of any one of claims 13 to 17 wherein the detecting means comprises electrical stimulation means for stimulation of the myocardium and detection means for detecting an increased pacing threshold.
20. The apparatus of any one of claims 13 to 17 wherein the detecting means comprises a catheter-mounted echocardiographic ultrasound crystal sensor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/829,457 US5222501A (en) | 1992-01-31 | 1992-01-31 | Methods for the diagnosis and ablation treatment of ventricular tachycardia |
US829,457 | 1992-01-31 | ||
PCT/US1993/000990 WO1993014711A1 (en) | 1992-01-31 | 1993-01-28 | Methods for the diagnosis and ablation treatment of ventricular tachycardia |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2128892A1 CA2128892A1 (en) | 1993-08-05 |
CA2128892C true CA2128892C (en) | 2002-09-17 |
Family
ID=25254596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002128892A Expired - Fee Related CA2128892C (en) | 1992-01-31 | 1993-01-28 | Methods for the diagnosis and ablation treatment of ventricular tachycardia |
Country Status (10)
Country | Link |
---|---|
US (2) | US5222501A (en) |
EP (1) | EP0625029B1 (en) |
JP (1) | JP3315697B2 (en) |
AT (1) | ATE181226T1 (en) |
AU (2) | AU659056B2 (en) |
CA (1) | CA2128892C (en) |
DE (1) | DE69325364T2 (en) |
NZ (1) | NZ249642A (en) |
WO (1) | WO1993014711A1 (en) |
ZA (1) | ZA93546B (en) |
Families Citing this family (249)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5588432A (en) * | 1988-03-21 | 1996-12-31 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials, and ablating tissue |
US5325860A (en) * | 1991-11-08 | 1994-07-05 | Mayo Foundation For Medical Education And Research | Ultrasonic and interventional catheter and method |
US5704361A (en) * | 1991-11-08 | 1998-01-06 | Mayo Foundation For Medical Education And Research | Volumetric image ultrasound transducer underfluid catheter system |
US5713363A (en) * | 1991-11-08 | 1998-02-03 | Mayo Foundation For Medical Education And Research | Ultrasound catheter and method for imaging and hemodynamic monitoring |
US5830209A (en) * | 1992-02-05 | 1998-11-03 | Angeion Corporation | Multi-fiber laser catheter |
USRE41334E1 (en) | 1992-09-23 | 2010-05-11 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Endocardial mapping system |
JP3581888B2 (en) * | 1992-09-23 | 2004-10-27 | エンドカーディアル・セラピューティクス・インコーポレーテッド | Endocardial mapping system |
US7189208B1 (en) * | 1992-09-23 | 2007-03-13 | Endocardial Solutions, Inc. | Method for measuring heart electrophysiology |
US7930012B2 (en) * | 1992-09-23 | 2011-04-19 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Chamber location method |
US5676693A (en) * | 1992-11-13 | 1997-10-14 | Scimed Life Systems, Inc. | Electrophysiology device |
US6161543A (en) | 1993-02-22 | 2000-12-19 | Epicor, Inc. | Methods of epicardial ablation for creating a lesion around the pulmonary veins |
US5571088A (en) * | 1993-07-01 | 1996-11-05 | Boston Scientific Corporation | Ablation catheters |
US5840031A (en) * | 1993-07-01 | 1998-11-24 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials and ablating tissue |
US5860974A (en) * | 1993-07-01 | 1999-01-19 | Boston Scientific Corporation | Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft |
CA2165829A1 (en) * | 1993-07-01 | 1995-01-19 | John E. Abele | Imaging, electrical potential sensing, and ablation catheters |
US5630837A (en) * | 1993-07-01 | 1997-05-20 | Boston Scientific Corporation | Acoustic ablation |
US5738096A (en) * | 1993-07-20 | 1998-04-14 | Biosense, Inc. | Cardiac electromechanics |
US5391199A (en) * | 1993-07-20 | 1995-02-21 | Biosense, Inc. | Apparatus and method for treating cardiac arrhythmias |
US6285898B1 (en) | 1993-07-20 | 2001-09-04 | Biosense, Inc. | Cardiac electromechanics |
US6983179B2 (en) | 1993-07-20 | 2006-01-03 | Biosense, Inc. | Method for mapping a heart using catheters having ultrasonic position sensors |
US5562619A (en) * | 1993-08-19 | 1996-10-08 | Boston Scientific Corporation | Deflectable catheter |
US5540723A (en) | 1993-10-06 | 1996-07-30 | Duke University | Method and apparatus for delivering an optimum shock duration in treating cardiac arrhythmias |
US5722400A (en) * | 1995-02-16 | 1998-03-03 | Daig Corporation | Guiding introducers for use in the treatment of left ventricular tachycardia |
US5462521A (en) * | 1993-12-21 | 1995-10-31 | Angeion Corporation | Fluid cooled and perfused tip for a catheter |
WO1995024160A1 (en) * | 1994-03-08 | 1995-09-14 | Cardima, Inc. | Intravascular rf occlusion catheter |
US5492126A (en) * | 1994-05-02 | 1996-02-20 | Focal Surgery | Probe for medical imaging and therapy using ultrasound |
US5715819A (en) * | 1994-05-26 | 1998-02-10 | The Carolinas Heart Institute | Microwave tomographic spectroscopy system and method |
US5876336A (en) * | 1994-10-11 | 1999-03-02 | Ep Technologies, Inc. | Systems and methods for guiding movable electrode elements within multiple-electrode structure |
US5941251A (en) * | 1994-10-11 | 1999-08-24 | Ep Technologies, Inc. | Systems for locating and guiding operative elements within interior body regions |
US5722402A (en) * | 1994-10-11 | 1998-03-03 | Ep Technologies, Inc. | Systems and methods for guiding movable electrode elements within multiple-electrode structures |
US5833673A (en) * | 1994-11-02 | 1998-11-10 | Daig Corporation | Guiding introducer system for use in the treatment of left ventricular tachycardia |
US5814029A (en) * | 1994-11-03 | 1998-09-29 | Daig Corporation | Guiding introducer system for use in ablation and mapping procedures in the left ventricle |
US6540755B2 (en) | 1995-02-14 | 2003-04-01 | Daig Corporation | Guiding introducers for use in the treatment of accessory pathways around the mitral valve using a retrograde approach |
WO1996025096A1 (en) * | 1995-02-17 | 1996-08-22 | Ep Technologies, Inc. | Acquisition of endocardially or epicardially paced electrocardiograms |
US5595183A (en) * | 1995-02-17 | 1997-01-21 | Ep Technologies, Inc. | Systems and methods for examining heart tissue employing multiple electrode structures and roving electrodes |
US5711305A (en) | 1995-02-17 | 1998-01-27 | Ep Technologies, Inc. | Systems and methods for acquiring endocardially or epicardially paced electrocardiograms |
ES2179183T3 (en) * | 1995-02-17 | 2003-01-16 | Boston Scient Ltd | SYSTEMS AND METHODS TO MAKE MEASUREMENTS, SEQUENTIAL IN TIME, OF BIOLOGICAL EPISODES. |
US5722416A (en) * | 1995-02-17 | 1998-03-03 | Ep Technologies, Inc. | Systems and methods for analyzing biopotential morphologies in heart tissue to locate potential ablation sites |
US5601088A (en) * | 1995-02-17 | 1997-02-11 | Ep Technologies, Inc. | Systems and methods for filtering artifacts from composite signals |
WO1996025094A1 (en) * | 1995-02-17 | 1996-08-22 | Ep Technologies, Inc. | Systems and methods for analyzing biopotential morphologies in body tissue |
US5605157A (en) * | 1995-02-17 | 1997-02-25 | Ep Technologies, Inc. | Systems and methods for filtering signals derived from biological events |
US6101409A (en) * | 1995-02-17 | 2000-08-08 | Ep Technologies, Inc. | Systems and methods for analyzing biopotential morphologies in body tissue |
US5609157A (en) * | 1995-02-17 | 1997-03-11 | Ep Technologies, Inc. | Systems and methods for analyzing biopotential morphologies in body tissue using iterative techniques |
US5630425A (en) * | 1995-02-17 | 1997-05-20 | Ep Technologies, Inc. | Systems and methods for adaptive filtering artifacts from composite signals |
US6409722B1 (en) | 1998-07-07 | 2002-06-25 | Medtronic, Inc. | Apparatus and method for creating, maintaining, and controlling a virtual electrode used for the ablation of tissue |
US5897553A (en) | 1995-11-02 | 1999-04-27 | Medtronic, Inc. | Ball point fluid-assisted electrocautery device |
US5538004A (en) * | 1995-02-28 | 1996-07-23 | Hewlett-Packard Company | Method and apparatus for tissue-centered scan conversion in an ultrasound imaging system |
US5817022A (en) * | 1995-03-28 | 1998-10-06 | Sonometrics Corporation | System for displaying a 2-D ultrasound image within a 3-D viewing environment |
US5795298A (en) * | 1995-03-28 | 1998-08-18 | Sonometrics Corporation | System for sharing electrocardiogram electrodes and transducers |
US5797849A (en) * | 1995-03-28 | 1998-08-25 | Sonometrics Corporation | Method for carrying out a medical procedure using a three-dimensional tracking and imaging system |
US5868673A (en) * | 1995-03-28 | 1999-02-09 | Sonometrics Corporation | System for carrying out surgery, biopsy and ablation of a tumor or other physical anomaly |
US5830144A (en) * | 1995-03-28 | 1998-11-03 | Vesely; Ivan | Tracking data sheath |
US6246898B1 (en) | 1995-03-28 | 2001-06-12 | Sonometrics Corporation | Method for carrying out a medical procedure using a three-dimensional tracking and imaging system |
AU740197B2 (en) * | 1995-06-07 | 2001-11-01 | Biosense, Inc. | Apparatus and method for treating cardiac arrhythmias with no discrete target |
US5954665A (en) * | 1995-06-07 | 1999-09-21 | Biosense, Inc. | Cardiac ablation catheter using correlation measure |
US5718241A (en) * | 1995-06-07 | 1998-02-17 | Biosense, Inc. | Apparatus and method for treating cardiac arrhythmias with no discrete target |
JP3782113B2 (en) * | 1995-06-12 | 2006-06-07 | コーディス ウェブスター,インコーポレイティド | Catheter with electromagnetic guidance sensor |
US5843144A (en) * | 1995-06-26 | 1998-12-01 | Urologix, Inc. | Method for treating benign prostatic hyperplasia with thermal therapy |
WO1997004702A1 (en) * | 1995-07-28 | 1997-02-13 | Ep Technologies, Inc. | Systems and methods for conducting electrophysiological testing using high-voltage energy pulses to stun heart tissue |
US6023638A (en) | 1995-07-28 | 2000-02-08 | Scimed Life Systems, Inc. | System and method for conducting electrophysiological testing using high-voltage energy pulses to stun tissue |
US6156031A (en) * | 1995-08-09 | 2000-12-05 | Eclipse Surgical Technologies | Transmyocardial revascularization using radiofrequency energy |
US5590657A (en) * | 1995-11-06 | 1997-01-07 | The Regents Of The University Of Michigan | Phased array ultrasound system and method for cardiac ablation |
US6915149B2 (en) | 1996-01-08 | 2005-07-05 | Biosense, Inc. | Method of pacing a heart using implantable device |
NL1003024C2 (en) | 1996-05-03 | 1997-11-06 | Tjong Hauw Sie | Stimulus conduction blocking instrument. |
US6283955B1 (en) | 1996-05-13 | 2001-09-04 | Edwards Lifesciences Corp. | Laser ablation device |
US5807383A (en) * | 1996-05-13 | 1998-09-15 | United States Surgical Corporation | Lasing device |
US5980545A (en) * | 1996-05-13 | 1999-11-09 | United States Surgical Corporation | Coring device and method |
US5861021A (en) * | 1996-06-17 | 1999-01-19 | Urologix Inc | Microwave thermal therapy of cardiac tissue |
US5699805A (en) * | 1996-06-20 | 1997-12-23 | Mayo Foundation For Medical Education And Research | Longitudinal multiplane ultrasound transducer underfluid catheter system |
US5720775A (en) * | 1996-07-31 | 1998-02-24 | Cordis Corporation | Percutaneous atrial line ablation catheter |
EP0932365A1 (en) * | 1996-10-17 | 1999-08-04 | Ethicon Endo-Surgery, Inc. | Methods and devices for improving blood flow to the heart of a patient |
US5989274A (en) * | 1996-10-17 | 1999-11-23 | Ethicon Endo-Surgery, Inc. | Methods and devices for improving blood flow to a heart of a patient |
US6805128B1 (en) | 1996-10-22 | 2004-10-19 | Epicor Medical, Inc. | Apparatus and method for ablating tissue |
US7052493B2 (en) | 1996-10-22 | 2006-05-30 | Epicor Medical, Inc. | Methods and devices for ablation |
US6311692B1 (en) * | 1996-10-22 | 2001-11-06 | Epicor, Inc. | Apparatus and method for diagnosis and therapy of electrophysiological disease |
US6719755B2 (en) | 1996-10-22 | 2004-04-13 | Epicor Medical, Inc. | Methods and devices for ablation |
US6840936B2 (en) | 1996-10-22 | 2005-01-11 | Epicor Medical, Inc. | Methods and devices for ablation |
US6059726A (en) * | 1996-11-08 | 2000-05-09 | The Regents Of The University Of California | Method for locating the atrio-ventricular (AV) junction of the heart and injecting active substances therein |
US6042581A (en) * | 1996-11-08 | 2000-03-28 | Thomas J. Fogarty | Transvascular TMR device and method |
US6165188A (en) * | 1996-12-02 | 2000-12-26 | Angiotrax, Inc. | Apparatus for percutaneously performing myocardial revascularization having controlled cutting depth and methods of use |
US6102926A (en) * | 1996-12-02 | 2000-08-15 | Angiotrax, Inc. | Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use |
US6120520A (en) | 1997-05-27 | 2000-09-19 | Angiotrax, Inc. | Apparatus and methods for stimulating revascularization and/or tissue growth |
US5931848A (en) * | 1996-12-02 | 1999-08-03 | Angiotrax, Inc. | Methods for transluminally performing surgery |
US6051008A (en) * | 1996-12-02 | 2000-04-18 | Angiotrax, Inc. | Apparatus having stabilization members for percutaneously performing surgery and methods of use |
US6071303A (en) * | 1996-12-08 | 2000-06-06 | Hearten Medical, Inc. | Device for the treatment of infarcted tissue and method of treating infarcted tissue |
US5947989A (en) * | 1996-12-12 | 1999-09-07 | United States Surgical Corporation | Method and apparatus for transmyocardial revascularization |
US6086534A (en) * | 1997-03-07 | 2000-07-11 | Cardiogenesis Corporation | Apparatus and method of myocardial revascularization using ultrasonic pulse-echo distance ranging |
US6019725A (en) * | 1997-03-07 | 2000-02-01 | Sonometrics Corporation | Three-dimensional tracking and imaging system |
US6263230B1 (en) | 1997-05-08 | 2001-07-17 | Lucent Medical Systems, Inc. | System and method to determine the location and orientation of an indwelling medical device |
US5879297A (en) | 1997-05-08 | 1999-03-09 | Lucent Medical Systems, Inc. | System and method to determine the location and orientation of an indwelling medical device |
US6129668A (en) * | 1997-05-08 | 2000-10-10 | Lucent Medical Systems, Inc. | System and method to determine the location and orientation of an indwelling medical device |
US6024740A (en) | 1997-07-08 | 2000-02-15 | The Regents Of The University Of California | Circumferential ablation device assembly |
US6012457A (en) | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
US5971983A (en) | 1997-05-09 | 1999-10-26 | The Regents Of The University Of California | Tissue ablation device and method of use |
US6171247B1 (en) | 1997-06-13 | 2001-01-09 | Mayo Foundation For Medical Education And Research | Underfluid catheter system and method having a rotatable multiplane transducer |
US5938660A (en) * | 1997-06-27 | 1999-08-17 | Daig Corporation | Process and device for the treatment of atrial arrhythmia |
US6251109B1 (en) * | 1997-06-27 | 2001-06-26 | Daig Corporation | Process and device for the treatment of atrial arrhythmia |
US6869431B2 (en) | 1997-07-08 | 2005-03-22 | Atrionix, Inc. | Medical device with sensor cooperating with expandable member |
US6997925B2 (en) * | 1997-07-08 | 2006-02-14 | Atrionx, Inc. | Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall |
US6966908B2 (en) | 1997-07-08 | 2005-11-22 | Atrionix, Inc. | Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall |
US6117101A (en) | 1997-07-08 | 2000-09-12 | The Regents Of The University Of California | Circumferential ablation device assembly |
US6500174B1 (en) | 1997-07-08 | 2002-12-31 | Atrionix, Inc. | Circumferential ablation device assembly and methods of use and manufacture providing an ablative circumferential band along an expandable member |
US6652515B1 (en) * | 1997-07-08 | 2003-11-25 | Atrionix, Inc. | Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall |
US6096037A (en) | 1997-07-29 | 2000-08-01 | Medtronic, Inc. | Tissue sealing electrosurgery device and methods of sealing tissue |
US6490474B1 (en) * | 1997-08-01 | 2002-12-03 | Cardiac Pathways Corporation | System and method for electrode localization using ultrasound |
US8709007B2 (en) | 1997-10-15 | 2014-04-29 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Devices and methods for ablating cardiac tissue |
US6135996A (en) * | 1998-04-17 | 2000-10-24 | Baxter International, Inc. | Controlled advancement lasing device |
US6107699A (en) * | 1998-05-22 | 2000-08-22 | Scimed Life Systems, Inc. | Power supply for use in electrophysiological apparatus employing high-voltage pulses to render tissue temporarily unresponsive |
US6428537B1 (en) | 1998-05-22 | 2002-08-06 | Scimed Life Systems, Inc. | Electrophysiological treatment methods and apparatus employing high voltage pulse to render tissue temporarily unresponsive |
US7670297B1 (en) | 1998-06-30 | 2010-03-02 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Chamber mapping system |
US7187973B2 (en) * | 1998-06-30 | 2007-03-06 | Endocardial Solutions, Inc. | Congestive heart failure pacing optimization method and device |
US7263397B2 (en) | 1998-06-30 | 2007-08-28 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and apparatus for catheter navigation and location and mapping in the heart |
US7806829B2 (en) * | 1998-06-30 | 2010-10-05 | St. Jude Medical, Atrial Fibrillation Division, Inc. | System and method for navigating an ultrasound catheter to image a beating heart |
US6706039B2 (en) | 1998-07-07 | 2004-03-16 | Medtronic, Inc. | Method and apparatus for creating a bi-polar virtual electrode used for the ablation of tissue |
US6537248B2 (en) * | 1998-07-07 | 2003-03-25 | Medtronic, Inc. | Helical needle apparatus for creating a virtual electrode used for the ablation of tissue |
US6950689B1 (en) | 1998-08-03 | 2005-09-27 | Boston Scientific Scimed, Inc. | Dynamically alterable three-dimensional graphical model of a body region |
US6059731A (en) * | 1998-08-19 | 2000-05-09 | Mayo Foundation For Medical Education And Research | Simultaneous side-and-end viewing underfluid catheter |
US8308719B2 (en) | 1998-09-21 | 2012-11-13 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Apparatus and method for ablating tissue |
US6245062B1 (en) | 1998-10-23 | 2001-06-12 | Afx, Inc. | Directional reflector shield assembly for a microwave ablation instrument |
US6607502B1 (en) | 1998-11-25 | 2003-08-19 | Atrionix, Inc. | Apparatus and method incorporating an ultrasound transducer onto a delivery member |
US6398736B1 (en) | 1999-03-31 | 2002-06-04 | Mayo Foundation For Medical Education And Research | Parametric imaging ultrasound catheter |
US6577902B1 (en) * | 1999-04-16 | 2003-06-10 | Tony R. Brown | Device for shaping infarcted heart tissue and method of using the device |
US8285393B2 (en) | 1999-04-16 | 2012-10-09 | Laufer Michael D | Device for shaping infarcted heart tissue and method of using the device |
US7226446B1 (en) | 1999-05-04 | 2007-06-05 | Dinesh Mody | Surgical microwave ablation assembly |
US6277113B1 (en) | 1999-05-28 | 2001-08-21 | Afx, Inc. | Monopole tip for ablation catheter and methods for using same |
CA2377583A1 (en) * | 1999-07-19 | 2001-01-25 | Epicor, Inc. | Apparatus and method for ablating tissue |
US7033352B1 (en) | 2000-01-18 | 2006-04-25 | Afx, Inc. | Flexible ablation instrument |
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US6447443B1 (en) | 2001-01-13 | 2002-09-10 | Medtronic, Inc. | Method for organ positioning and stabilization |
US8221402B2 (en) | 2000-01-19 | 2012-07-17 | Medtronic, Inc. | Method for guiding a medical device |
US7706882B2 (en) | 2000-01-19 | 2010-04-27 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area |
US6692450B1 (en) | 2000-01-19 | 2004-02-17 | Medtronic Xomed, Inc. | Focused ultrasound ablation devices having selectively actuatable ultrasound emitting elements and methods of using the same |
US6409720B1 (en) | 2000-01-19 | 2002-06-25 | Medtronic Xomed, Inc. | Methods of tongue reduction using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US6595934B1 (en) * | 2000-01-19 | 2003-07-22 | Medtronic Xomed, Inc. | Methods of skin rejuvenation using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US6413254B1 (en) | 2000-01-19 | 2002-07-02 | Medtronic Xomed, Inc. | Method of tongue reduction by thermal ablation using high intensity focused ultrasound |
US6361531B1 (en) | 2000-01-21 | 2002-03-26 | Medtronic Xomed, Inc. | Focused ultrasound ablation devices having malleable handle shafts and methods of using the same |
US8083736B2 (en) | 2000-03-06 | 2011-12-27 | Salient Surgical Technologies, Inc. | Fluid-assisted medical devices, systems and methods |
US8048070B2 (en) | 2000-03-06 | 2011-11-01 | Salient Surgical Technologies, Inc. | Fluid-assisted medical devices, systems and methods |
US6577904B1 (en) | 2000-03-30 | 2003-06-10 | Cardiac Pacemakers, Inc. | Ultrasound echogenic cardiac lead |
US6673068B1 (en) | 2000-04-12 | 2004-01-06 | Afx, Inc. | Electrode arrangement for use in a medical instrument |
US20020107514A1 (en) | 2000-04-27 | 2002-08-08 | Hooven Michael D. | Transmural ablation device with parallel jaws |
US6905498B2 (en) | 2000-04-27 | 2005-06-14 | Atricure Inc. | Transmural ablation device with EKG sensor and pacing electrode |
US6932811B2 (en) | 2000-04-27 | 2005-08-23 | Atricure, Inc. | Transmural ablation device with integral EKG sensor |
AU2001253654A1 (en) | 2000-04-27 | 2001-11-12 | Medtronic, Inc. | Vibration sensitive ablation apparatus and method |
US6488680B1 (en) | 2000-04-27 | 2002-12-03 | Medtronic, Inc. | Variable length electrodes for delivery of irrigated ablation |
US6546935B2 (en) * | 2000-04-27 | 2003-04-15 | Atricure, Inc. | Method for transmural ablation |
US6514250B1 (en) | 2000-04-27 | 2003-02-04 | Medtronic, Inc. | Suction stabilized epicardial ablation devices |
AU6321301A (en) * | 2000-05-16 | 2001-11-26 | Atrionix Inc | Apparatus and method incorporating an ultrasound transducer onto a delivery member |
ATE290827T1 (en) | 2000-06-13 | 2005-04-15 | Atrionix Inc | SURGICAL ABLATION PROBE FOR FORMING AN ANNUAL LESION |
DE60134982D1 (en) * | 2000-07-13 | 2008-09-04 | Abbott Cardiovascular Systems | INTRODUCTION SYSTEM FOR MYOCARDIAL, CELLULAR MATERIAL |
US6926669B1 (en) | 2000-10-10 | 2005-08-09 | Medtronic, Inc. | Heart wall ablation/mapping catheter and method |
US20020087151A1 (en) | 2000-12-29 | 2002-07-04 | Afx, Inc. | Tissue ablation apparatus with a sliding ablation instrument and method |
US20040138621A1 (en) | 2003-01-14 | 2004-07-15 | Jahns Scott E. | Devices and methods for interstitial injection of biologic agents into tissue |
US7628780B2 (en) | 2001-01-13 | 2009-12-08 | Medtronic, Inc. | Devices and methods for interstitial injection of biologic agents into tissue |
US7740623B2 (en) | 2001-01-13 | 2010-06-22 | Medtronic, Inc. | Devices and methods for interstitial injection of biologic agents into tissue |
US7250048B2 (en) | 2001-04-26 | 2007-07-31 | Medtronic, Inc. | Ablation system and method of use |
US6807968B2 (en) | 2001-04-26 | 2004-10-26 | Medtronic, Inc. | Method and system for treatment of atrial tachyarrhythmias |
US6699240B2 (en) | 2001-04-26 | 2004-03-02 | Medtronic, Inc. | Method and apparatus for tissue ablation |
US6648883B2 (en) | 2001-04-26 | 2003-11-18 | Medtronic, Inc. | Ablation system and method of use |
US7959626B2 (en) * | 2001-04-26 | 2011-06-14 | Medtronic, Inc. | Transmural ablation systems and methods |
US6663627B2 (en) | 2001-04-26 | 2003-12-16 | Medtronic, Inc. | Ablation system and method of use |
FR2831743B1 (en) * | 2001-10-25 | 2004-01-30 | Cit Alcatel | IS-IS FAULT TOLERANT ROUTING SYSTEM AND CORRESPONDING METHOD |
US8175680B2 (en) * | 2001-11-09 | 2012-05-08 | Boston Scientific Scimed, Inc. | Systems and methods for guiding catheters using registered images |
US7542807B2 (en) * | 2001-12-04 | 2009-06-02 | Endoscopic Technologies, Inc. | Conduction block verification probe and method of use |
US6656175B2 (en) | 2001-12-11 | 2003-12-02 | Medtronic, Inc. | Method and system for treatment of atrial tachyarrhythmias |
US7099717B2 (en) | 2002-01-03 | 2006-08-29 | Afx Inc. | Catheter having improved steering |
US6827715B2 (en) | 2002-01-25 | 2004-12-07 | Medtronic, Inc. | System and method of performing an electrosurgical procedure |
US7967816B2 (en) | 2002-01-25 | 2011-06-28 | Medtronic, Inc. | Fluid-assisted electrosurgical instrument with shapeable electrode |
US7192427B2 (en) | 2002-02-19 | 2007-03-20 | Afx, Inc. | Apparatus and method for assessing transmurality of a tissue ablation |
US7310545B1 (en) * | 2002-04-12 | 2007-12-18 | Medtronic, Inc. | Method and device to form a sensor using isolated cardiomyocytes |
US20040106896A1 (en) * | 2002-11-29 | 2004-06-03 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
US6932804B2 (en) | 2003-01-21 | 2005-08-23 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
EP1503819A4 (en) * | 2002-05-08 | 2007-07-25 | Univ California | System and method for forming a non-ablative cardiac conduction block |
US7118566B2 (en) | 2002-05-16 | 2006-10-10 | Medtronic, Inc. | Device and method for needle-less interstitial injection of fluid for ablation of cardiac tissue |
US7294143B2 (en) | 2002-05-16 | 2007-11-13 | Medtronic, Inc. | Device and method for ablation of cardiac tissue |
US6786202B2 (en) * | 2002-09-24 | 2004-09-07 | Caterpillar Inc | Hydraulic pump circuit |
US7291161B2 (en) | 2002-10-02 | 2007-11-06 | Atricure, Inc. | Articulated clamping member |
US7083620B2 (en) | 2002-10-30 | 2006-08-01 | Medtronic, Inc. | Electrosurgical hemostat |
US7317950B2 (en) * | 2002-11-16 | 2008-01-08 | The Regents Of The University Of California | Cardiac stimulation system with delivery of conductive agent |
US7288092B2 (en) | 2003-04-23 | 2007-10-30 | Atricure, Inc. | Method and apparatus for ablating cardiac tissue with guide facility |
US7497857B2 (en) | 2003-04-29 | 2009-03-03 | Medtronic, Inc. | Endocardial dispersive electrode for use with a monopolar RF ablation pen |
US7112196B2 (en) * | 2003-06-13 | 2006-09-26 | Piezo Technologies, Inc. | Multi-element array for acoustic ablation |
US7789877B2 (en) * | 2003-07-02 | 2010-09-07 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Ablation catheter electrode arrangement |
US8308708B2 (en) * | 2003-07-15 | 2012-11-13 | Abbott Cardiovascular Systems Inc. | Deployment system for myocardial cellular material |
US20050059448A1 (en) * | 2003-09-11 | 2005-03-17 | Scott Sims | Method and apparatus for playing card game |
US8147486B2 (en) * | 2003-09-22 | 2012-04-03 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Medical device with flexible printed circuit |
US7229437B2 (en) * | 2003-09-22 | 2007-06-12 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Medical device having integral traces and formed electrodes |
US7234225B2 (en) * | 2003-09-22 | 2007-06-26 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method for manufacturing medical device having embedded traces and formed electrodes |
US20050251127A1 (en) * | 2003-10-15 | 2005-11-10 | Jared Brosch | Miniature ultrasonic transducer with focusing lens for intracardiac and intracavity applications |
US7530980B2 (en) | 2004-04-14 | 2009-05-12 | Atricure, Inc | Bipolar transmural ablation method and apparatus |
US8333764B2 (en) | 2004-05-12 | 2012-12-18 | Medtronic, Inc. | Device and method for determining tissue thickness and creating cardiac ablation lesions |
ATE547990T1 (en) | 2004-05-14 | 2012-03-15 | Medtronic Inc | DEVICES FOR TREATING AFRICIA BY MASS ABLATION |
US20050261571A1 (en) * | 2004-05-21 | 2005-11-24 | Willis Nathaniel P | 3-D ultrasound navigation during radio-frequency ablation |
US7974674B2 (en) * | 2004-05-28 | 2011-07-05 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Robotic surgical system and method for surface modeling |
US8755864B2 (en) * | 2004-05-28 | 2014-06-17 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Robotic surgical system and method for diagnostic data mapping |
US10258285B2 (en) * | 2004-05-28 | 2019-04-16 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Robotic surgical system and method for automated creation of ablation lesions |
US7632265B2 (en) * | 2004-05-28 | 2009-12-15 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Radio frequency ablation servo catheter and method |
US9782130B2 (en) | 2004-05-28 | 2017-10-10 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Robotic surgical system |
US10863945B2 (en) * | 2004-05-28 | 2020-12-15 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Robotic surgical system with contact sensing feature |
US8528565B2 (en) | 2004-05-28 | 2013-09-10 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Robotic surgical system and method for automated therapy delivery |
ATE466536T1 (en) | 2004-06-02 | 2010-05-15 | Medtronic Inc | COMPOSITE BIPOLAR ABLATION DEVICE |
EP1761188B1 (en) | 2004-06-02 | 2011-07-20 | Medtronic, Inc. | Clamping ablation tool |
WO2005120376A2 (en) * | 2004-06-02 | 2005-12-22 | Medtronic, Inc. | Ablation device with jaws |
WO2005120375A2 (en) | 2004-06-02 | 2005-12-22 | Medtronic, Inc. | Loop ablation apparatus and method |
US8663245B2 (en) | 2004-06-18 | 2014-03-04 | Medtronic, Inc. | Device for occlusion of a left atrial appendage |
US8409219B2 (en) | 2004-06-18 | 2013-04-02 | Medtronic, Inc. | Method and system for placement of electrical lead inside heart |
US8926635B2 (en) | 2004-06-18 | 2015-01-06 | Medtronic, Inc. | Methods and devices for occlusion of an atrial appendage |
US20070156210A1 (en) * | 2005-01-14 | 2007-07-05 | Co-Repair, Inc., A California Corporation | Method for the treatment of heart tissue |
US7455670B2 (en) * | 2005-01-14 | 2008-11-25 | Co-Repair, Inc. | System and method for the treatment of heart tissue |
US20060270900A1 (en) * | 2005-05-26 | 2006-11-30 | Chin Albert K | Apparatus and methods for performing ablation |
US8932208B2 (en) | 2005-05-26 | 2015-01-13 | Maquet Cardiovascular Llc | Apparatus and methods for performing minimally-invasive surgical procedures |
US8155910B2 (en) * | 2005-05-27 | 2012-04-10 | St. Jude Medical, Atrial Fibrillation Divison, Inc. | Robotically controlled catheter and method of its calibration |
US7684870B1 (en) * | 2005-11-18 | 2010-03-23 | Pacesetter, Inc. | Direct current fibrillator |
US20080039746A1 (en) | 2006-05-25 | 2008-02-14 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
EP2209517A4 (en) | 2007-10-05 | 2011-03-30 | Maquet Cardiovascular Llc | Devices and methods for minimally-invasive surgical procedures |
WO2009086448A1 (en) | 2007-12-28 | 2009-07-09 | Salient Surgical Technologies, Inc. | Fluid-assisted electrosurgical devices, methods and systems |
CN101909516B (en) * | 2007-12-28 | 2012-07-04 | 皇家飞利浦电子股份有限公司 | Tissue ablation device with photoacoustic lesion formation feedback |
WO2009140359A2 (en) | 2008-05-13 | 2009-11-19 | Medtronic, Inc. | Tissue lesion evaluation |
US9254168B2 (en) | 2009-02-02 | 2016-02-09 | Medtronic Advanced Energy Llc | Electro-thermotherapy of tissue using penetrating microelectrode array |
JP5592409B2 (en) | 2009-02-23 | 2014-09-17 | サリエント・サージカル・テクノロジーズ・インコーポレーテッド | Fluid-assisted electrosurgical device and method of use thereof |
US8545412B2 (en) * | 2009-05-29 | 2013-10-01 | Boston Scientific Scimed, Inc. | Systems and methods for making and using image-guided intravascular and endocardial therapy systems |
WO2011031748A1 (en) | 2009-09-08 | 2011-03-17 | Salient Surgical Technologies, Inc. | Cartridge assembly for electrosurgical devices, electrosurgical unit and methods of use thereof |
US20110213260A1 (en) * | 2010-02-26 | 2011-09-01 | Pacesetter, Inc. | Crt lead placement based on optimal branch selection and optimal site selection |
EP2544616B1 (en) | 2010-03-11 | 2017-09-06 | Medtronic Advanced Energy LLC | Bipolar electrosurgical cutter with position insensitive return electrode contact |
US20110295249A1 (en) * | 2010-05-28 | 2011-12-01 | Salient Surgical Technologies, Inc. | Fluid-Assisted Electrosurgical Devices, and Methods of Manufacture Thereof |
US9138289B2 (en) | 2010-06-28 | 2015-09-22 | Medtronic Advanced Energy Llc | Electrode sheath for electrosurgical device |
US8920417B2 (en) | 2010-06-30 | 2014-12-30 | Medtronic Advanced Energy Llc | Electrosurgical devices and methods of use thereof |
US8906012B2 (en) | 2010-06-30 | 2014-12-09 | Medtronic Advanced Energy Llc | Electrosurgical devices with wire electrode |
US9724010B2 (en) | 2010-07-08 | 2017-08-08 | Emtensor Gmbh | Systems and methods of 4D electromagnetic tomographic (EMT) differential (dynamic) fused imaging |
US9023040B2 (en) | 2010-10-26 | 2015-05-05 | Medtronic Advanced Energy Llc | Electrosurgical cutting devices |
EP2640272B1 (en) * | 2010-11-18 | 2020-07-01 | Koninklijke Philips N.V. | Apparatus for being used for detecting a property of a periodically moving object |
US9427281B2 (en) | 2011-03-11 | 2016-08-30 | Medtronic Advanced Energy Llc | Bronchoscope-compatible catheter provided with electrosurgical device |
US9750565B2 (en) | 2011-09-30 | 2017-09-05 | Medtronic Advanced Energy Llc | Electrosurgical balloons |
US8870864B2 (en) | 2011-10-28 | 2014-10-28 | Medtronic Advanced Energy Llc | Single instrument electrosurgery apparatus and its method of use |
US9149200B2 (en) * | 2012-05-08 | 2015-10-06 | Northwestern University | Using intracardiac electrograms to predict location of fibrosis and autonomic nerves in the heart |
WO2014081992A2 (en) | 2012-11-21 | 2014-05-30 | Emtensor Gmbh | Electromagnetic tomography solutions for scanning head |
US10912476B2 (en) | 2013-01-16 | 2021-02-09 | University Of Vermont | Catheters, systems, and related methods for mapping, minimizing, and treating cardiac fibrillation |
US9033893B2 (en) | 2013-01-16 | 2015-05-19 | Universtiy of Vermont | Methods and systems for assessing cardiac fibrillogenicity |
US9072449B2 (en) | 2013-03-15 | 2015-07-07 | Emtensor Gmbh | Wearable/man-portable electromagnetic tomographic imaging |
US20140275944A1 (en) | 2013-03-15 | 2014-09-18 | Emtensor Gmbh | Handheld electromagnetic field-based bio-sensing and bio-imaging system |
US9974599B2 (en) | 2014-08-15 | 2018-05-22 | Medtronic Ps Medical, Inc. | Multipurpose electrosurgical device |
US11389227B2 (en) | 2015-08-20 | 2022-07-19 | Medtronic Advanced Energy Llc | Electrosurgical device with multivariate control |
US11051875B2 (en) | 2015-08-24 | 2021-07-06 | Medtronic Advanced Energy Llc | Multipurpose electrosurgical device |
DK3361955T3 (en) | 2015-10-16 | 2020-10-26 | Emtensor Gmbh | ELECTROMAGNETIC INTERFERENCE PATTERN RECOGNITION TOMOGRAPHY |
US10716612B2 (en) | 2015-12-18 | 2020-07-21 | Medtronic Advanced Energy Llc | Electrosurgical device with multiple monopolar electrode assembly |
EP3397149A4 (en) | 2015-12-30 | 2019-08-14 | Schuler Scientific Solutions, LLC | Tissue mapping and treatment |
EP3544513B1 (en) | 2016-11-23 | 2023-06-28 | Emtensor GmbH | Use of electromagnetic field for tomographic imaging of head |
US10194975B1 (en) | 2017-07-11 | 2019-02-05 | Medtronic Advanced Energy, Llc | Illuminated and isolated electrosurgical apparatus |
DE102017010318B8 (en) * | 2017-11-07 | 2019-09-12 | Hochschule Offenburg | Esophageal electrode probe and device for cardiac treatment and / or diagnosis |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4785815A (en) * | 1985-10-23 | 1988-11-22 | Cordis Corporation | Apparatus for locating and ablating cardiac conduction pathways |
US4641649A (en) * | 1985-10-30 | 1987-02-10 | Rca Corporation | Method and apparatus for high frequency catheter ablation |
US4940064A (en) * | 1986-11-14 | 1990-07-10 | Desai Jawahar M | Catheter for mapping and ablation and method therefor |
DE3718139C1 (en) * | 1987-05-29 | 1988-12-08 | Strahlen Umweltforsch Gmbh | Cardiac catheter |
US4928695A (en) * | 1989-02-17 | 1990-05-29 | Leon Goldman | Laser diagnostic and treatment device |
US4936281A (en) * | 1989-04-13 | 1990-06-26 | Everest Medical Corporation | Ultrasonically enhanced RF ablation catheter |
US5056517A (en) * | 1989-07-24 | 1991-10-15 | Consiglio Nazionale Delle Ricerche | Biomagnetically localizable multipurpose catheter and method for magnetocardiographic guided intracardiac mapping, biopsy and ablation of cardiac arrhythmias |
US5010886A (en) * | 1989-08-18 | 1991-04-30 | Intertherapy, Inc. | Medical probe assembly having combined ultrasonic imaging and laser ablation capabilities |
-
1992
- 1992-01-31 US US07/829,457 patent/US5222501A/en not_active Expired - Lifetime
-
1993
- 1993-01-26 ZA ZA93546A patent/ZA93546B/en unknown
- 1993-01-28 AT AT93905790T patent/ATE181226T1/en not_active IP Right Cessation
- 1993-01-28 WO PCT/US1993/000990 patent/WO1993014711A1/en active IP Right Grant
- 1993-01-28 CA CA002128892A patent/CA2128892C/en not_active Expired - Fee Related
- 1993-01-28 EP EP93905790A patent/EP0625029B1/en not_active Expired - Lifetime
- 1993-01-28 JP JP51351793A patent/JP3315697B2/en not_active Expired - Fee Related
- 1993-01-28 DE DE69325364T patent/DE69325364T2/en not_active Expired - Lifetime
- 1993-01-28 NZ NZ249642A patent/NZ249642A/en not_active IP Right Cessation
- 1993-01-28 AU AU36575/93A patent/AU659056B2/en not_active Ceased
- 1993-05-19 US US08/065,886 patent/US5323781A/en not_active Expired - Lifetime
-
1994
- 1994-11-17 AU AU78878/94A patent/AU661259B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO1993014711A1 (en) | 1993-08-05 |
EP0625029B1 (en) | 1999-06-16 |
US5323781A (en) | 1994-06-28 |
AU7887894A (en) | 1995-02-16 |
ZA93546B (en) | 1994-11-11 |
AU659056B2 (en) | 1995-05-04 |
AU661259B2 (en) | 1995-07-13 |
US5222501A (en) | 1993-06-29 |
JP3315697B2 (en) | 2002-08-19 |
CA2128892A1 (en) | 1993-08-05 |
ATE181226T1 (en) | 1999-07-15 |
AU3657593A (en) | 1993-09-01 |
DE69325364T2 (en) | 2000-05-25 |
NZ249642A (en) | 1996-09-25 |
DE69325364D1 (en) | 1999-07-22 |
EP0625029A1 (en) | 1994-11-23 |
JPH07506737A (en) | 1995-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2128892C (en) | Methods for the diagnosis and ablation treatment of ventricular tachycardia | |
WU et al. | Exercise-triggered paroxysmal ventricular tachycardia: A repetitive rhythmic activity possibly related to afterdepolarization | |
Stevenson et al. | Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. | |
Kramer et al. | Intramural reentry as a mechanism of ventricular tachycardia during evolving canine myocardial infarction. | |
Morady et al. | Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. | |
Lee et al. | Reentrant wave fronts in Wiggers’ stage II ventricular fibrillation: characteristics and mechanisms of termination and spontaneous regeneration | |
Schoels et al. | Circus movement atrial flutter in the canine sterile pericarditis model. Activation patterns during initiation, termination, and sustained reentry in vivo. | |
Waldo et al. | Surgical treatment of life-threatening ventricular arrhythmias: the role of intraoperative mapping and consideration of the presently available surgical techniques | |
Sra et al. | Electroanatomically guided catheter ablation of ventricular tachycardias causing multiple defibrillator shocks | |
Gillette et al. | Successful surgical treatment of atrial, junctional, and ventricular tachycardia unassociated with accessory connections in infants and children | |
Cox et al. | Perinodal cryosurgery for atrioventricular node reentry tachycardia in 23 patients | |
Gallagher et al. | Cryothermal mapping of recurrent ventricular tachycardia in man. | |
Hunt et al. | Comparison of early and late dimensions and arrhythmogenicity of cryolesions in the normothermic canine heart | |
Ruffy et al. | Termination of ventricular tachycardia by single extrastimulation during the ventricular effective refractory period. | |
Cao et al. | Cardiac arrhythmias: Catheter ablation of incessant ventricular tachycardia: acute and long-term results | |
Schweikert et al. | Epicardial Access: Present and Future Applications for Interventional Electrophysiologists | |
Kavanagh et al. | High-current stimuli to the spared epicardium of a large infarct induce ventricular tachycardia. | |
Wiener et al. | Epicardial activation in patients with coronary artery disease: effects of regional contraction abnormalities. | |
Chilson et al. | Chemical ablation of ventricular tachycardia in the dog | |
Gang et al. | Closed chest catheter ablation of an accessory pathway in a patient with permanent junctional reciprocating tachycardia | |
Cinca et al. | Reciprocating tachycardia using bilateral anomalous pathways: electrophysiologic and clinical implications. | |
Marchlinski et al. | Experimental myocardial cryoinjury: local electromechanical changes, arrhythmogenicity, and methods for determining depth of injury | |
Mason et al. | The mechanisms of ventricular tachycardia in humans determined by intraoperative recording of the electrical activation sequence | |
Kawamura et al. | Mapping of septal ventricular tachycardia: Clinical and experimental correlations | |
Klein et al. | Surgical therapy of cardiac arrhythmias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130128 |